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1.  ABSTRACT 
 
Autism Spectrum Disorders (ASDs) represent a group of childhood neurodevelopmental 
and neuropsychiatric disorders characterized by deficits in verbal communication, 
impairment of social interaction, and restricted and repetitive patterns of interests and 
behaviours. Evidences indicate that ASDs have strong genetic bases. Known 
chromosomal anomalies, rare genetic variants and single nucleotide polymorphisms 
(SNPs) have been related to ASD phenotypes in many studies. Furthermore Comparative 
Genomic Hybridization (CGH) studies have revealed copy number variations (CNVs) as 
risk factors. Recently, several studies have suggested that lymphoblastoid cells (LCLs) 
can discriminate between ASDs and control samples.  
This study is part of a Telethon project which has been started in 2009 and involves 
different Italian clinical and research groups; it aims to analyze gene expression 
variations in ASD subjects, characterized for CNVs potentially involved in the onset of 
autism. Transcriptome from LCLs of 27 ASD probands and 23 health controls have been 
analyzed through Next Generation Sequencing technology (RNA Sequencing). 
Gene set enrichment analysis (GSEA), on the total cohort and on a subgroup with a 
22q13.3 deletion, revealed that autoimmune disorders and antigen processing and 
presentation pathways are the most enriched ones. Subgroup’s GSEA highlights the 
involvement of axon guidance pathway, confirming that LCLs could exhibit biomarkers 
relevant to autism. Moreover, we demonstrate that three outlier genes cluster within a 
CNV on 16p13.1, suggesting that this is a potential candidate ASD region. This study 
provides evidence that potentially causative structural variants have a functional impact 
via transcriptome alterations in ASDs at a genome wide level and demonstrates the 
utility of integrating gene expression with mutation data. 
Further analysis of differentially expressed genes and CNVs not selected in this study will 
help understanding the genetic bases for ASD pathophysiology and unravelling potential 
new pathways involved in ASDs. 
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1.1 Riassunto 
I disordini dello spettro autistico (ASDs) sono caratterizzati dalla compromissione 
dell’interazione sociale e della comunicazione verbale e non verbale, e da 
comportamenti ripetitivi e stereotipati. L’autismo è una delle più frequenti tra le 
malattie complesse ereditabili, tuttavia, solo pochi geni implicati nell’eziologia sono stati 
identificati. 
Negli ultimi anni, in diversi studi, sono stati individuati polimorfismi a singolo nucleotide 
(SNP), anomalie cromosomiche e rare varianti genetiche associati al fenotipo autistico. 
Inoltre, in studi di ibridazione genomica comparativa (CGH), come fattori di rischio sono 
state individuate alcune variazioni del numero di copie (CNV). Altri studi hanno 
evidenziato che le cellule linfoblastoidi possono discriminare tra soggetti con ASD e 
campioni di controllo. 
Il presente studio è parte di un progetto Telethon, avviato nel 2009, che coinvolge 
diversi gruppi italiani di clinica e di ricerca. Questo progetto ha l’obiettivo di analizzare le 
variazioni di espressione genica in 27 soggetti con ASD e 23 controlli sani. I probandi 
selezionati presentano CNV potenzialmente coinvolte nell'insorgenza dell'autismo. Il 
trascrittoma di 27 probandi e 23 controlli sani è stato analizzato attraverso la tecnica di 
sequenziamento di nuova generazione dell’RNA (RNA sequencing). 
L’analisi di arricchimento del gruppo di geni (GSEA) risultati differenzialmente espressi, 
compiuta sull’intera coorte e su un sottogruppo con una delezione 22q13.3, ha rilevato 
che i principali pathway arricchiti appartengono ai disturbi autoimmuni e al pathway di 
presentazione dell'antigene. La sottoanalisi compiuta sui campioni con la delezione 
evidenzia il coinvolgimento di geni appartenenti al pathway di orientamento degli 
assoni, confermando che le linee cellulari linfoblastoidi possono presentare biomarcatori 
rilevanti per l'autismo. Inoltre, abbiamo dimostrato che tre geni “outlier” clusterizzano 
all'interno di una CNV sul cromosoma 16p13.1, suggerendo che questo è un potenziale 
candidato locus per autismo.  
Questo studio fornisce la prova che le varianti strutturali, potenzialmente causative di 
ASD, hanno un impatto funzionale attraverso alterazioni del trascrittoma e dimostra 
l'utilità di integrare i dati di espressione genica con i dati genomici. 
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Ulteriori analisi sui geni differenzialmente espressi e su CNVs, non selezionate in questo 
studio, contribuiranno a mettere in rilievo le basi genetiche e fisiopatologiche di ASD e 
ad evidenziare nuovi potenziali pathway coinvolti nei disordini dello spettro autistico. 
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2. INTRODUCTION 
 
Autism is a neurodevelopmental disorder in the category of pervasive developmental 
disorders, and is characterized by severe and pervasive impairment in reciprocal 
socialization, qualitative impairment in communication, and repetitive or unusual 
behavior. The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-
IV-TR; American Psychiatric Association, 2000) and the International Classification of 
Diseases, 10th edition (ICD-10; World Health Organization, 1992), include autistic 
disorder, Asperger’s syndrome, pervasive developmental disorder-not otherwise 
specified (PDD-NOS), Rett’s syndrome, and childhood disintegrative disorder as 
pervasive developmental disorders. Clinicians and researchers use autism spectrum 
disorders (ASDs) to include autism, Asperger’s syndrome, and PDD-NOS. For children 
with Rett’s disorder or childhood disintegrative disorder, clinical course, patho-
physiology, and the diagnostic strategies used are different. 
2.1 Epidemiology 
The population prevalence of ASDs is debated, estimates published in 2012 by the 
Centers for Disease Control and Prevention (CDC) state that the incidence of ASDs is 1 
out of 88 children in the United States, as many as 1 in 500 individuals have autism, 
making it one of the most common neurodevelopmental disorders (Prevalence of 
autism spectrum disorders-Autism and developmental disabilities monitoring network, 
2012). ASDs are most often diagnosed before age of four, and are at least three to four 
times more common in males than females (Fombonne E., 2005). 
2.2 History and definitions of ASDs 
In 1943 Leo Kanner, in a paper entitled Autistic Disturbances of Affective Contact,  which 
went on to become a classic in the field of clinical psychiatry, described eleven children 
with “infantile autism” a distinct syndrome instead of previous depictions of such 
children as feeble-minded, retarded, moronic, idiotic or schizoid (Kanner L., 1943). The 
spectrum of clinical conditions labeled autism soon expanded beyond Kannerʼs ﬁrst 
description. In 1944, one year after Kannerʼs paper, Hans Asperger described children 
that he also called “autistic”, but who seemed to have high non-verbal intelligence 
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quotients and who used a large vocabulary appropriately. Confusion remains about the 
distinction between Asperger syndrome and high-functioning autism for many years. 
Ever since the recognition and description of autism by Kanner, scientists and clinicians 
alike have been searching for the cause of this disorder or group of disorders. Initially, 
although Kanner in his original paper hypothesized that autism was an inborn biologic 
condition, misconceptions based on psychoanalytic theory led workers to view autism as 
psychiatric disorder. The major proponent of the purely psychiatric approach was Bruno 
Bettelheim (1967) who attributed the disorder to an unnurturing mother, called the 
“refrigerator theory”. Autism remained an esoteric disorder for several decades until 
physicians and parents connected these symptoms with an increasing number of 
patients. The idea of autism as a psychiatric disorder persisted until the 1960s when 
Rimland (1968) hypothesized a neurologic basis. 
Clinical definitions of autism continue to evolve. The current DSM-IV-TR includes autism 
in a broad category of pervasive developmental disorders. This spectrum blurs at the 
edges with disruptive behavior, communication disorders and intellectual disability at 
one end, and with behaviors now thought to be normal at the other. Repeated revision 
and expansion of the diagnostic categories has probably contributed to the gradual 
increase in the reported prevalence of autism spectrum disorders that has been evident 
since the mid-1980s.  
The American Psychiatric Association (APA) has proposed new diagnostic criteria for the 
fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for 
autism. The APA’s extensive development process of the fifth edition of the DSM is 
nearing its conclusion and final publication is planned for May 2013. The proposal by the 
DSM-5 Neurodevelopmental Work Group recommends a new category called autism 
spectrum disorder, which would incorporate several previously separate diagnoses, 
including autistic disorder, Asperger’s disorder, childhood disintegrative disorder and 
PDD-NOS. Proposed DSM-5 criteria are being tested in real-life clinical settings known as 
field trials. Field testing of the proposed criteria for ASD does not indicate that there will 
be any change in the number of patients receiving care for ASDs in treatment centers, 
just more accurate diagnoses that can lead to more focused treatment. 
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Controversies over clinical definitions may only be resolved with the discovery of 
biomarkers (biochemical, anatomical or physiological measures) that are specific to one 
or more aspects of autism. Biomarkers are essential for an understanding of brain 
mechanisms underlying the various autisms, and for the development of useful 
therapeutics. 
2.3 Clinical characteristics and assessment 
Symptoms of ASDs affect three core domains: socialization, communication, and 
behavior (Figure 1). Autism is a disorder that usually begins in infancy, at the latest, in 
the first three years of life, but typical language development might delay identification 
of symptoms. 
 
Fig 1. Core domains of autism (Levy et al, 2009). 
Diagnoses show heterogeneity of clinical phenotype, severity, and type and frequency of 
symptoms. Indeed, autism is a heterogeneous condition; no two children or adults with 
autism have exactly the same profile, but difficulties fall into the three core domains 
that are reliably measured and usually consistent across time, even though specific 
behaviors may change with development. ASDs have characteristic diagnostic criteria: 
ages of symptom recognition, associated medical and developmental features, standard 
effective treatments, and usual courses of development (Figure 2). 
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In addition, autism affects not only social behavior and language but also many other 
aspects of functioning, including sensory responsiveness, play, and motor activity. 
Approximately 30% of autistic patients also have an associated seizure disorder. Many, 
but not all, individuals with autism, have mental retardation and almost all individuals 
with autism have a history of language delay. However, there are ASD subjects in which 
neither language delay nor mental retardation is present (e.g., Asperger's disorder). 
 
Fig 2. Differential diagnostic features of autism spectrum disorders (Levy et al, 2009). 
Diagnostic assessment of ASDs includes use of ICD or DSM-IV-TR diagnostic criteria, and 
standardized methods to assess core (Figure 1) and comorbid symptoms. This 
multidisciplinary assessment includes a review of caregiver concerns, descriptions of 
behavior, medical history, and questionnaires (Charman T. et al, 2002). 
The gold standard assessment methods based on DSM-IV-TR criteria for the evaluation 
of suspected ASDs are the Autism Diagnostic Observation Schedule (ADOS) (Lord C. et al, 
2000) and the Revised Autism Diagnostic Interview (ADI-R) (Le Couteur A. et al, 1989). 
These tools, requiring training and reliability testing, have improved accuracy and 
reliability of diagnosis. The ADI-R provides a standardized, semi-structured interview and 
a diagnostic algorithm for the DSM-IV and the ICD-10 definitions of autism; because of 
the time needed for administration (1-3h), its use is precluded in many clinical settings. 
The ADOS is a semi-structured, standardized assessment in which the researcher 
observes the social interaction, communication, play and imaginative use of materials 
for children suspected of having autism. Final autism case diagnosis is defined as 
meeting criteria on the communication, social, and repetitive behaviors domains of the 
 __________________________________________________________________ 
  10 
 
ADI-R and scoring at or above the cut off for autistic disorder on the ADOS module 1 or 
2, used with children who do not consistently use phrase speech or are not verbally 
fluent. 
A comprehensive diagnostic assessment should include medical investigation for causes 
and associated diagnoses (Freitag CM., 2007). An appropriate medical investigation for 
causes comprises a detailed history and physical examination (with careful examination 
for dysmorphology). Clinical genetic assessment might include laboratory studies 
referral to a clinical geneticist. Genetic laboratory studies should cover routine 
karyotype and molecular DNA testing for fragile X, or Comparative Genomic 
Hybridisation (CGH), or both (Schaefer GB. et al, 2008). Associated medical problems 
such as seizures show a need for electroencephalogram (EEG), substantial regression a 
need for metabolic investigation, and abnormal head size a need for neuroimaging in 
some.  
2.4 Neurobiology 
Attempts to identify unified theories explaining core and comorbid deficits have been 
unsuccessful, which is not surprising in view of the heterogeneous expression of ASDs. In 
studies (DiCicco-Bloom E. et al, 2006) of this disorder as a neurodevelopmental disorder 
of prenatal and postnatal brain development, researchers have attempted to elucidate 
these theories by examination of brain growth, functional neural networks, 
neuropathology, electrophysiology, and neurochemistry. Neurocognitive theories 
include pragmatic language impairment and difficulties in intersubjectivity (theory of 
mind), executive function and problem-solving mindset, weak central coherence and 
difficulty with integration of information into meaningful wholes (Volkmar FR. et al, 
2003), and deficits in connectivity and processing demands (Minshew NJ. et al, 2007). 
Neurobiological findings support different theories. Macrocephaly is noted by age 2–3 
years in 20% of children with ASDs. Brain growth accelerates at 12 months (Minshew NJ. 
et al, 2007). These changes arise in parallel with onset of core symptoms during the first 
2 years of life. Results of neuroimaging studies (Pardo CA. et al, 2007) have shown 
overgrowth in cortical white matter and abnormal patterns of growth in the frontal lobe, 
temporal lobes, and limbic structures such as the amygdala. These brain regions are 
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implicated in development of social, communication, and motor abilities that are 
impaired in ASDs.  
Functional magnetic resonance imaging (MRI) has shown differences in patterns of 
activation and timing of synchronisation across cortical networks, with lowered 
functional connectivity relating to language, working memory, social cognition or 
perception, and problem solving. The most reliably replicated functional MRI abnormal 
finding is hypoactivation of the fusiform face area, associated with deficits in perception 
of people compared with objects (DiCicco-Bloom E. et al, 2006; Schultz RT., 2005).  
Neurochemical investigations with animal models and empirical drug studies remain 
inconclusive. Serotonin and genetic differences in serotonin transport seem to have the 
most empirical evidence for a role in ASDs (Lam KSL. et al, 2006), whereas data lending 
support to the roles of dopaminergic and glutaminergic systems are presently less 
robust, but are evolving. Study of the role of the dopaminergic and cholinergic system, 
oxytocin, and aminoacid neurotransmitters shows promise (Lam KSL. et al, 2006). 
Together, results of clinical, neuroimaging, neuropathological, and neurochemical 
studies (Pardo CA. et al, 2007) show that ASDs are disorders of neuronal-cortical 
organisation that cause deficits in information processing in the nervous system, ranging 
from synaptic and dendritic organisation to connectivity and brain structure. These 
changes probably alter developmental trajectory of social communication and seem to 
be affected by genetic and environmental factors. 
2.5 Causes 
There is strong evidence for a genetic influence in ASDs and more recently there has 
been some association of autism with low birth weight infants and with older parents. 
However, the proposed etiologies that have been the most controversial, and have had 
the most significant effect on the health of children, concern the possible association of 
toxins and vaccines with autism. Mercuric compounds are nephrotoxic and neurotoxic at 
high doses. Thimerosal, a preservative used widely in vaccine formulations, contains 
ethylmercury. Thus it has been suggested that childhood vaccination with thimerosal-
containing vaccine could be causally related to neurodevelopmental disorders such as 
autism. Results of different studies do not support a causal relationship between 
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childhood vaccination with thimerosal-containing vaccines and development of ASDs 
(Hviid A. et al, 2003; Farrington CP. et al, 2001; DeStefano F. 2007). 
One of the first areas of interest in the 1960s and 1970s was the search for an infectious 
agent that might be involved in the etiology of ASDs (Chess S., 1971). However, after 
decades of research no definite role for infectious agents in autism etiology has been 
confirmed. On the other hand, these endeavors have led to observations that perhaps 
the immune system was involved in autism, and evidence continues to mount that 
immune abnormalities are indeed associated with ASDs. 
Several sources of evidence found during last decades suggest that strong genetic 
components are involved in susceptibility to ASDs: there are much higher concordance 
rates of ASDs in monozygotic twins (92%) than dizygotic twins (10%), and recent 
estimate of the sibling recurrence risk ratio (λs) for autism is 22 [min 9, max 45], 
corresponding to an increase of 45- to 150-fold. These values make this disorder the 
neuropsychiatric disorder most affected by genetic factors (Bailey A. et al, 1995; 
Lauritsen MB. et al, 2005). 
ASDs are multifactorial, with many risk factors acting together to produce the 
phenotype. The difference between monozygotic and dizygotic concordance rates 
suggests some risk factors interact (ie, gene–gene or gene–environmental interactions). 
These effects could be a result of toxic environmental factors or epigenetic factors that 
alter gene functions, in turn altering neural tissue. Epigenetic factors can be specific 
aspects of the physical environment (eg, biochemically active compounds) or specific 
types of psychological experiences (eg, stress) that alter brain chemistry, turn genes off 
or on at specific times during development, or regulate gene expression in other ways. 
The possible role of environmental and epigenetic factors is an area being studied. 
2.6 Genetics of ASDs 
ASD genes have been difficult to identify, despite the high heritability of the disorder. 
Approximately  10-15% of cases may be due to an  identifiable Mendelian condition or 
genetic syndrome (including chromosomal anomalies). Rett syndrome, fragile X 
syndrome (0-20%), neurofibromatosis type I (NF1; 0.2-14%), tuberous sclerosis (TSC; 0.4-
2.9%) are the most frequently cited Mendelian conditions. Other rare microdeletion or 
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single-gene defects have been associated with ASDs, including those found in Williams, 
Sotos, Cowden, Moebius, and Timothy syndromes. ASDs may also occur in some 
mitochondrial diseases and untreated phenylketonuria. In addition, cytogenetically 
visible anomalies on all chromosomes are observed in ASDs (Abrahams BS. et al, 2008; 
Zafeiriou DI. et al, 2007). The 22q13.3 deletion causes a neurodevelopmental syndrome, 
also known as Phelan-McDermid syndrome, characterized by developmental delay, 
severe delay or absence of expressive speech (Phelan  MC. et al, 2001) and autistic-like 
behavior (Goizet C. et al, 2000). The genotype-phenotype study suggests that the 22q13 
deletion phenotype has to be attributed to SHANK3 gene disruption. SHANK3 is strongly 
expressed in the cerebral cortex and cerebellum and has been proposed as the major 
cause for both the neurological features of the 22q13 deletion syndrome and for a 
monogenic form of autism (Bonaglia MC. et al, 2001). 
However, the remaining 90% of ASDs, while highly familial, have unknown genetic 
etiology. Thus, it seems reasonable to accelerate the gene discovery process by using 
combinations of experimental approaches, such as the study of single gene or more 
simple causes, such as chromosomal copy number imbalances whose phenotypes 
include ASDs. It is also likely that inherited epigenetic modifications and gene by gene 
and gene by environmental interactions are significant sources of variation (Farber CR. 
et al, 2009). 
Insights into underlying biological mechanisms for ASDs have been gained from study of 
syndromes with increased rates of this disorder. For example, functions of the genes 
underlying fragile X (FMR1) and Rett’s syndrome (MECP2) implicate synaptic dysfunction 
in cause and pathogenesis (Ramocki MD. et al, 2008). Further evidence  for synaptic 
dysfunction as a unifying cause has come from studies on rare mutations in genes 
coding for neural cell adhesion and synaptic molecules (Tabuchi K. et al, 2007). 
Convergence of genetic discoveries with implications for synaptic maturation is 
especially notable because findings from neuroimaging research also suggest that 
structural and functional brain connectivity is aberrant in ASDs (Minshew NJ. et al, 
2007). Thus, genetic and neurobiological evidence point to a good causal model of this 
disorder genetically mediated by abnormalities of synaptic maturation and connectivity.  
There are two alternative proposals, one involving numerous rare genetic mutations and 
the other involving fewer but more common genetic variations. Supporting the rare 
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mutation hypothesis are mutations in several genes and rare structural DNA variations 
both of which have been identified, although the pervasiveness of these effects remains 
controversial (Weiss LA. et al, 2008; Sebat J. et al, 2007). Data supporting the effect of 
common variation have been more difficult to find. Only a few common variants have 
been identified as possible candidate genes in linkage and association studies (Veenstra-
Vanderweele J. et al, 2004), and many of these have not been replicated in subsequent 
independent sample studies. Moreover, more recent studies are identifying a growing 
number of distinct and individually rare genetic causes, suggesting that the genetic 
architecture of ASDs may have significant contribution  from heterogeneous rare 
variants.  
Since 2003 (Volkmar FR. et al, 2003) a number of approaches are being used to elucidate 
the association between specific genes and autism. Whereas genome screens (whole 
genome sequencing, SNP-array) search for common genetic markers in populations of 
multiplex families with autism, Comparative Genomic Hybridization studies search for 
inherited or spontaneous genetic abnormalities on an individual basis (Muhle R. et al, 
2004). 
Genome wide linkage scans, as genetic approach to identify susceptibility genes, is very 
powerful, but the heterogeneity present within autism families has led thus far to mixed 
success in identifying candidate genes (Benayed R. et al, 2005; Ma DQ. et al, 2005).  
Genome-wide association studies (GWAS) compare the DNA of people with and without 
a disorder using thousands or millions of markers scattered throughout their genomes. 
However, GWAS can only point to large chromosome regions rather than identifying 
particular genes or gene mutations. The first GWAS on autism, published in 2009, 
implicated two regions with mild effects: one on chromosome 5, and one on 
chromosome 20 (Weiss LA. et al, 2009). Subsequent GWAS on autism have failed to turn 
up any other parts of the genome with statistical significance.  
One possible interpretation of these data is that genetic risk factors may contribute 
combinatorially to each of the three phenotypic domains of ASDs. This line of reasoning 
suggests that there are genetic variants that influence independently social behavior, 
language development, and behavioral flexibility, and that ASDs result from a 
confluence of multiple genetic risk factors for each of the three domains. An alternative 
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hypothesis is that the core phenotypes that characterize ASDs are mediated through a 
common biological mechanism, and thus the three domains are not separable. In the 
latter hypothesis, the observed genetic complexity is due to vulnerability imparted by 
multiple genes encoding proteins within a common biological pathway (Campbell DB. et 
al, 2010). 
The evaluation of linkage peaks extended beyond genes with selective brain expression 
to consider the complex medical conditions seen in autism patients. In addition to the 
well known behavioral core features, some individuals with autism exhibit 
gastrointestinal, immunological, or nonspecific neurological symptoms (Valicenti-
McDermott M. et al, 2006; White JF. 2003). Although the degree to which individuals 
with autism exhibit more medical complications compared with typical individuals is 
debated, it is possible that autism vulnerability could include genes involved more 
broadly in multiple biological processes that impact the development and function of 
the brain and other organ systems in parallel. 
2.6.1 Copy Number Variants 
Another promising development in understanding the genetics of ASDs is the discovery 
of variations in the gene copy number as a risk factor (Sebat J. et al, 2007). Copy-number 
variation (CNV) is a structural variation in the genome, ranging from a few thousand to 
several million base pairs, in which material is either duplicated or deleted. A number of 
population-based studies have shown that this type of genomic variant can affect as 
much as 12% of the human genome (Redon R. et al, 2006). Many studies have gone on 
to demonstrate the importance of CNVs in determining human phenotypic variation and 
disease susceptibility (Perry GH. et al,2007; Craddock N. et al, 2010). CNVs can be de 
novo or inherited. Almost all these variations are deletions, with many fragments 
containing several genes (Cook EH. et al,2008). De-novo CNVs seem to be strongly 
associated with intellectual impairment and dysmorphology (Sebat J. et al, 2007). Most 
seem to be individually unique, although we do not know the full implications of them 
because their relation to phenotype is not established (Cook EH. et al,2008), and 
affected siblings do not always share specific variations (Marshall CR. et al, 2008). 
Furthermore, to recognize whether a given de-novo variant is abnormal is difficult 
because the population distribution of specific CNVs is unknown. 
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Comparative Genomic Hybridization (CGH) and other molecular cytogenetic techniques 
are methods to identify and quantify DNA copy number changes across the genome, 
enabling the characterization of chromosomal variations with confidence. These 
techniques are discovering an increasing number of copy number variations in 
individuals with ASDs. A catalogue of this structural variation is provided by the 
Database of Genomic Variants (DGV, http://projects.tcag.ca/variation/) and currently 
covers about 29% of the human genome. 
In particular, the application of array CGH for genome-wide screening has a major 
impact on clinical genetic diagnosis. First, array CGH made it possible to identify 
submicroscopic aberrations in at least 9% of patients with idiopathic mental retardation 
(Buysse K. et al, 2009a). Second, it facilitated the identification of disease genes of some 
well-known clinical syndromes (Vissers LE. et al, 2004; Kleefstra T. et al, 2006) and led to 
the characterization of many novel microdeletion and microduplication syndromes 
(Buysse K. et al, 2009b; Menten B. et al, 2007; Slavotinek AM. 2008). Finally, it has 
contributed to the elucidation of the mechanisms causing genomic disorders (Gu W. et 
al, 2008). Array CGH technology also facilitated the discovery of a new important source 
of human genetic variation.  
Studies on both humans and mice have shown that CNVs can influence gene expression 
(Stranger BE. et al, 2007; Henrichsen CN. et al, 2009). This has led many scientists to 
hypothesize that these heterozygous CNVs may influence susceptibility to 
neurodevelopmental disorders through a gene-dosage mechanism. For instance, it is 
easy to imagine how mild perturbations in axon guidance molecules could affect critical 
stages of brain development. Others have looked for evidence of an alternative 
mechanism whereby deletions might unmask recessive coding changes in the opposite 
allele (Flipsen-ten Berg K. et al, 2007; Pagnamenta AT. et al, 2011; Vorstman JA. et al, 
2011). A third possible mechanism exists for deletions or duplications with breakpoints 
disrupting two different genes. Where the two neighboring genes are encoded on the 
same chromosomal strand, such CNVs could potentially result in gene-fusion transcripts. 
A number of genomic rearrangements that lead to fusion transcripts have already been 
described in autism and schizophrenia (Pagnamenta AT. et al, 2010; Walsh T. et al, 2008; 
Zhou X. et al, 2010). If such transcripts are stable they may be translated into novel 
proteins with a possibility for deleterious gain-of-function effects. 
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The discovery of rare and recurrent CNVs as important pathogenic mutations in ASDs 
was a watershed in ASD genetics. Recurrent CNVs such as those at 16p11.2, 22q11.2, 
1q21.1, 7q11.23 and 15q11-q13 show statistically significant association with ASDs. 
However, the functional impact of these CNVs on downstream RNA expression at both a 
collective and individual level remains largely unknown. Because CNVs alter copy 
number and must presumably act via changes in downstream gene expression, an initial 
study that explored the transcriptome-wide effects of CNVs reported that changes in 
gene copy number explained roughly 20% of detected transcriptional alterations. 
Although widely assumed, it remains unknown whether rare CNVs identified in autistic 
individuals have similar effects on transcription levels and subsequent pathophysiology. 
Alternative lines of evidence, such as gene-expression data, might confirm the presence 
of functional alterations related to a particular CNV and would thus be of significant 
utility. 
2.6.2 Gene expression analyses 
The transcriptome is the complete set of transcripts in a cell, and their quantity, for a 
specific developmental stage or physiological condition. Although transcriptomes are 
more dynamic than genomic DNA, these molecules provide direct access to gene 
regulation and protein information. Understanding the transcriptome is, therefore, 
essential for interpreting the functional elements of the genome and revealing the 
molecular constituents of cells and tissues, and also for understanding development and 
disease. 
RNA-Sequencing is a recently developed approach for gene expression analysis based on 
deep-sequencing technologies. Next Generation Sequencing (NGS) has revolutionized 
the genetic landscape yielding results never before achieved. The output of this method 
is the number of transcripts that were produced in a cell under chosen conditions. RNA-
Seq is also possible to use in studying alternative splicing, novel exons, exon-exon 
junctions or even novel genes. General advantages of RNA-Seq in comparison with 
previous techniques (i.e. microarrays, SAGE, CAGE, MPSS, Northern blot and qRT-PCR)  
are unlimited range of gene expression, much more higher sensitivity and ability to 
control regions with high similarity (single base resolution), ability to work with low 
amount of RNA, there is no need to know genes a priori (genes can be assembled de 
novo) and low-intensity background bias. 
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Geschwind and colleagues used RNA-Seq to profile the transcriptomes of 244 people 
with autism and members of their family in order to get a sense of which genetic 
mutations led to real changes in gene expression (Voineagu I. et al, 2011). Geschwind's 
study found that many of these genes with altered expression patterns were clustered 
in pathways known to play important roles in neuron function, development and 
structure (Luo R. et al, 2012). This discovery suggests common mechanisms through 
which seemingly different gene mutations could cause disease.  
Moreover, Geschwind's team analysed gene expression patterns in the brains of 19 
people with autism and without, using brain tissue collected after each person's death 
(Voineagu I. et al, 2011). For each brain, the scientists studied three different regions, all 
thought to be important in autism. They found that in people with autism, two regions 
of the brain that normally have distinct patterns of gene expression - the frontal and 
temporal lobes of the cerebral cortex - instead had almost identical patterns, with the 
same genes switched on or off. The altered genetics suggest a lack of specialization 
among some brain cells, which could lead to differences in how the brain processes 
information. 
However, the number of postmortem brain tissues from individuals with autism is 
limited, which potentially erodes this avenue of analysis. An alternative that has 
emerged is the field of blood genomics, where peripheral lymphocytes are used to 
represent the transcriptome. 
2.6.3 Lymphoblastoid Cell Lines 
While studies of gene expression in brain tissue may lead to a better understanding of 
the mechanistic basis for ASD, it is not an appropriate target for diagnostic assays. 
Ideally, diagnostic assays should use easily obtained patient samples such as blood, 
considering there is evidence that gene expression and other markers exist in the 
peripheral blood of ASD patients. 
Blood genomics is beginning to be applied to the study of central nervous system (CNS) 
disorders; studies have demonstrated that genes expressed in the peripheral blood can 
classify CNS disorders and may be able to identify and predict the genes and 
pathobiologies involved in these disorders (Tang Y. et al, 2003; Tang Y. et al, 2004). 
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In addition, several studies have suggested that B-lymphoblastoid cells lines (LCLs) 
transformed with Epstein-Barr virus (EBV) can be used to detect biologically plausible 
correlations between candidate genes and neuropsychiatric diseases, including Rett 
syndrome (Horike S. et al, 2005), nonspecific X-linked mental retardation (Meloni I. et al, 
2002), bipolar disorder (Iwamoto K. et al, 2004), fragile X syndrome (Brown V. et al, 
2001; Nishimura Y. et al, 2007) and dup(15q) (Baron CA. et al, 2006a; Baron CA. et al, 
2006b).  
In particular, Hu et al, 2006 provided proof-of-principle that LCLs (and possibly their 
precursor peripheral blood cells) exhibit biomarkers relevant to autism, and further 
suggest their potential usefulness as reporter cells in developing a diagnostic screen for 
autism (Hu VW. et al, 2006). 
Using patient lymphoblastoid cells in genetic studies will ensure adequate genetic 
material for current and future analyses. LCLs can also provide other biomolecules for 
use in transcriptomics, proteomics, metabolomics, and other types of analyses. In 
functional analyses, LCLs have been used as surrogate or cellular models in the study of 
diseases. However, care must be taken to determine the suitability of using transformed 
B cells in certain experiments. Despite some inherent limitations, the utility of LCLs is 
increasingly recognized, and with appropriate infrastructure and financial support, LCLs 
will be an important resource for genetic and functional research of neurological 
disorders. 
While it is unlikely that RNA-Seq studies on LCL will identify the etiology(ies) of autism, 
this global approach to gene expression analyses is expected to highlight molecular or 
pathway defects related to the pathophysiology of the condition which, in turn, can be 
targeted for drug therapies. Moreover, as opposed to fixed autopsy tissues in which RNA 
may have degraded, a live cell model can also be used to examine the functional 
consequences of the genomic alteration(s) and the efficacy of different pharmacological 
agents in ameliorating the impaired function. 
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2.7 Aim of the study 
This study is part of a Telethon project which has been started in 2009 and involves 
different Italian clinical and research groups. It aims to analyze differentially expressed 
genes through the next generation sequencing technology (RNASeq) in ASD subjects, 
previously characterized for CNVs potentially involved in the onset of autism. 
Because brain or neuronal tissue are not available, we used lymphoblastoid cells lines 
(LCLs). We presume that combining genome array-CGH and RNASeq there will be much 
more opportunities to decipher the complex nature of these diseases. 
In particular, the goals of the work are: to evaluate downstream effects of CNVs on gene 
expression and correlate genomic imbalances and transcriptome with ASD phenotypes. 
This research will further help understanding the genetic bases for ASD pathophysiology 
and unravelling potential new pathways involved in ASDs. 
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3. MATERIALS AND METHODS 
 
3.1 Sample collection 
Ascertaining of autistic subjects and their affected and unaffected family member as a 
part of Telethon Project was done through the following neurology centers of excellence 
for the study of autism and neurodevelopmental disorders: Istituto IRCSS Neurologico 
Nazionale C. Besta (Milan), Unit of Neurology of the Oasi Institute for Research on 
Mental Retardation and Brain Aging (Troina-EN) , Unità di Neuropsichiatria Infantile - 
ASL 20 (Verona). 
The enrolment of the patient will be done  according the following protocol. A case 
individual is eligible for inclusion in this research project only if all the following criteria 
apply: 
• Meet DSM-IV-TR criteria for PDD/ASD and reach score cut-off in Autism 
Diagnostic Interview-Revised (ADI-R) (Le Couteur A. et al, 1989) and/or Autism 
Diagnostic Observation Schedule-Generic (ADOS-G) (Lord C. et al, 2000), 
• Be at least 3 years of age at the time of entering the research project 
• Have at least one parent or legal guardian giving voluntary written consent for 
their children to take part to this research project. 
The exclusion criteria are as follows: 
• Presence of profound mental retardation 
• History of serious head injury, encephalitis or tumors 
• Presence of metabolic disease or genetic syndrome of known cause 
• Age older than 18. 
The following current clinical protocol will be administered to all recruited patients: 
• Physical examination 
• Neurological examination 
• Instrumental and laboratory exams: 
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− genetic (Karyotype, Fragile-X, subtelomeric analysis), 
− metabolic screenings (blood and urine amino acids, urinary organic acids, 
urinary mucopolysaccharides, blood and urine uric acid), 
− neurophysiologic (sleep EEG), 
− neurological imaging (investigation or acquisition of previous MRI scan of 
adequate quality and performed not earlier than three years). 
• Battery of psychopathological and neuropsychological assessment: 
− ADI-R: a standardized, semi structured, investigator-based interview for 
caregiver of subjects with possible ASD. The item focus primarily on the 
three domains of functioning – language/communication; reciprocal social 
interactions; and restricted, repetitive, and stereotyped behaviors and 
interests- that are specified as of diagnostic importance in international 
diagnostic manuals. 
− ADOS-G: a semi structured assessment of communication, social interaction, 
and play or imaginative use of materials which is usually videotaped. It 
consists of standard activities that allow the examiner to observe directly 
behaviors that have been identified as relevant to the diagnosis of ASD at 
different developmental levels and chronological ages. 
− Intelligence (i.e. Wechsler Scales or Leiter-R) or developmental Scales (i.e. 
Griffiths Mental Developmental Scales) to evaluate cognitive abilities. In 
circumstances in which detailed psychometric testing has been undertaken 
the Vineland Adaptive Scale (Sparrow SS. et al, 1985) may be used to a 
screening tool to assess developmental level. 
Written informed consent was obtained from all study participants after a full 
explanation of the study. The research protocol was in accordance with Helsinki 
Declaration. 
Fifty nine families with an ASD proband, for a total of 217 individuals, were enrolled. 
Most of the families are composed of one affected child (23) or one affected child plus 
an healthy sibling (20). Multiplex families (9 with 2, 1 with 3 and 1 with 4 non affected 
children) are present and in 5 families only one parent was available. Moreover, 8 
unrelated children, affected by 22q13.3 deletion syndrome, also known as  Phelan-
McDermid syndrome, have been collected. Subject distribution is given in figure 3.  
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Fig 3. Families distribution according to the number of subjects. (a): 8 unfamiliar cases. (b) and (c): one affected child with 
one or both parents, respectively. From (d) to (g): one affected child, parents plus healthy siblings. 
3.2 Lymphoblastoid cell lines (LCLs) establishment 
EBV transformed lymphoblastoid cell lines were established for 106 subjects at 
University of Verona using standard protocol (ECACC, European Collection of Cell 
Coltures). LCLs are generated by EBV transformation of the B-lymphocyte component 
within the PBL population. 
3.2.1 EBV isolation 
The marmoset cell line B95-8 is a continuous line permissive for Epstein-Barr virus (EBV) 
replication that releases high titres of transforming EBV.  
The B95-8 cell line, grown in RPMI 1640 medium (Euroclone, Milano, Italy), 10% fetal 
calf serum (FCS; Euroclone)  at 37°C in a humidified 5% CO2 chamber, has to be 
expanded until the concentration of 1x10
6
/ml and a final volume of 400 ml. To induce 
the lytic cycle cells have to be transferred in RMPI 1640 medium, 2% FCS at 33°C with a 
initial concentration of 0.2x10
6
/ml for two weeks . The decrease temperature and serum 
concentration induce the lytic cycle of EBV. All cells have to be removed by 
centrifugation for 5 min at 180 x g, then the supernatant has to be filtered through a 
0.45 µm filter. The supernatant then is aliquoted and stored at -80°C. 
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3.2.2 Isolation of Mononuclear Cells from Peripheral Blood
For lymphocyte separation, 6 ml of whole blood from 106
volume of 26 ml with medium RPMI1640 (isotonic solution) and layered carefully over 
Ficoll-Paque™ PLUS (without intermixing) in a centrifuge tube. After a centrifugation at 
room temperature (typically at 400 g for 30
together with monocytes and platelets) are harvested fr
4). This material is then centrifuged twice in medium RPMI1640 solution to wash the 
lymphocytes and to remove the platelets.
Fig 4. Lymphocyte separation using Ficoll
plasma and erythrocytes, thus is possible the harvesting of lymphocytes layer. 
3.2.3 B-lymphocytes infection
B lymphocytes were exposed to a 
37°C, 5% CO2. After infections, cells with EBV are centrifuged  for 5 min at 400 x 
eliminate superrnatant, LCLs are then resuspended in complete medium (RPMI 1640 
medium  supplemented with 20% feta
L-glutamine (Euroclone), fungizone 250ng/ml (Gibco, Life Technologies), and 2mM 
penicillin streptomycin (Life Technologies, Carlsbad, CA)supplemented with 
phytohemagglutinin (PHA; 500µg/ml; Sigma Aldrich) an
EBV enters B cells, the EBV genome has been reported to exist as distinct, high
episomal copies, as well as nonrandom integration to B cells (Gualandi G. et al, 1992; 
Lestou VS. et al, 1993; Leenman EE. et al, 2004; G
allowed to proliferate and are subsequently maintained in growth medium before 
cryopreservation.  
 24 
 
 subjects is diluted to the final 
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om the interface layer (Figure 
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standard virus dose (1 aliquot of 1ml) for an hour at 
l bovine serum (FBS; Euroclone) and a mix of 2mM 
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LCLs were maintained in complete medium at 37°C in a humidified 5% CO2 chamber for 
about 6 weeks at which time wells with typical foci of EBV-transformed lymphoblastoid 
cells were scored positive. The cell lines were treated with a standardized procedure, to 
minimize environmental variation. Cell lines were harvested at a density of 0.8–1x10
6
 
cells/ml at least 85% viability for a minimum of 50 million cells per line. LCLs were spun 
for 5 min at 400 x g, and the resulting pellets were lysed with Trizol (Life Technologies, 
Carlsbad, CA) to obtain a final concentration of 10x10
6
 cells/ml. Cells in Trizol were 
stored at -80°C. Other 25 million cells per line were spun for 5 min 400 x g, the pellet 
was resuspended in freezing medium (RPMI 1640, 20% FBS, 10% dimethylsulfoxide, 
DMSO) at the minimum concentration of 5x10
6
 cells/ml. Cells were stored, first, at -80°C 
in Cryovials, using Nalgene® Cryo 1% freezing container, then were transferred in liquid 
nitrogen. 
As mycoplasma infections in cultured cells tend to induce both biochemical and genetic 
changes, experimental results can often be misinterpreted. Therefore, contamination 
surveys should be periodically conducted. First, genomic DNA from each lines was 
extracted via the standard protocols described by Tang J. (2000). Then, each cell line was 
tested for the presence of mycoplasma using PCR-based method for the detection of 
16S and 23S rRNA genes of 13 species using mycoplasma primers and conditions 
described by Sung H. (2006). Aliquots of the final PCR products were analyzed on 2% 
agarose gel. DNA bands were visualized with a UV transilluminator after GelRed™ 
staining, and then photographed. 
3.3 RNA extraction 
Total RNA from 50 LCLs samples was extracted using Trizol Reagent, a ready-to-use 
reagent for the isolation of total RNA,  that maintains the integrity of the RNA, while 
disrupting cells and dissolving cell components. 
 1 mL of Trizol reagent is used per 10 x 10
6
 cells that are lysed by repetitive pipetting. 
The homogenized samples are incubated for 5 minutes at 15 to 30°C to permit the 
complete dissociation of nucleoprotein complexes then is added 0.2 mL of chloroform 
per 1 mL of Trizol Reagent. Tubes should be capped securely and shacked vigorously by 
hand for 15 seconds and then let them at 15 to 30°C for 2 to 3 minutes. Samples are 
centrifuged at 12,000 x g for 15 minutes at 4°C. Following centrifugation, the mixture 
 __________________________________________________________________ 
  26 
 
separates into a lower red, phenol-chloroform phase, an interphase, and a colorless 
upper aqueous phase. RNA remains exclusively in the aqueous phase. The aqueous 
phase is transferred into a fresh tube. 
Precipitation of the RNA from the aqueous phase is done by adding 0.5 mL of isopropyl 
alcohol and incubating samples at 15 to 30°C for 10 minutes. After a centrifugation at 
12,000 x g for 10 minutes at 4°C the RNA precipitates and forms a gel-like pellet on the 
side and bottom of the tube. The supernatant is removed and the RNA pellet is washed 
once adding at least 1 mL of 75% ethanol. The sample is mixed by inversion and 
centrifuged at 7,600 x g for 5 minutes at 4°C. At the end of the procedure, briefly the 
RNA pellet has to be dried (air-dry for 5-10 minutes) and resuspended in 20 µl of water 
nuclease-free. Finally RNA is stored at -80°C. 
An additional DNAse digestion step was performed to ensure that the samples were not 
contaminated with genomic DNA.  0.1 volume 10X TURBO DNase Buffer and 1 µL of 
TURBO DNase are added to a 7500ng of RNA, mixing gently. After an incubation at 37°C 
for 20-30 min, the resuspended DNase Inactivation Reagent is added to the solution. 
Finally, the solution is centrifuged at 10000 x g for 1.5 min and the supernatant is 
transferred to a fresh tube. 
3.4 RNA quantification and quality analysis 
RNA quantity was assessed using the ND-1000 Nanodrop (Thermo Scientific, 
Wilmington, DE, US) which enables highly accurate UV/Vis analyses of 1µl sample with 
remarkable reproducibility. Pure RNA has a 260/280 Abs ratio of 1.8/2.0 and a 260/230 
Abs ratio of 1.8/2.0. 
RNA was further analyzed for quality control by use of the RNA 6000 Nano LabChip 
(Agilent Technologies, Santa Clara, CA, US). Due to the omnipresence of RNases, and the 
instability of RNA, integrity checks and sample quantization are essential steps before 
any RNA dependent application. The RNA Nano kits (Agilent Technologies, Santa Clara, 
CA, US) allow the quantization and integrity analysis of total RNA as well as the 
visualization of rRNA impurities in mRNA samples. It also generates the RNA Integrity 
Number (RIN) based on a numbering system from 1 to 10, with 1 being the most 
degraded profile and 10 being the most intact.  
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150 ng of RNA were loaded into a chip system that contains up to 12 microcapillaries  
filled with a special matrix for the separation of RNA molecules according to their 
molecular weight. The chip is loaded into the Agilent 2100 Bioanalyzer, an electric field 
is applied and a short round of electrophoresis produces a complete separation of all the 
RNA molecules . Capillaries are then scanned by a laser source and two types of results 
are retrieved (Figure 5): 
− An electropherogram with peaks corresponding to RNA molecules of different 
weight (28S, 18S, 5S) and whose subtended area is proportional to the 
abundance of a specific RNA; 28S should be twice abundant 18S area for the 
RNA best quality, 
− An image of virtual agarose gel separation. 
 
Fig 5. Agilent 2100 Bioanalyzer output of one control. This sample had a RIN of 10 and a 28S/18S of 2.2. 
3.5 RNA Sequencing 
RNA Sequencing experiments have been conducted in collaboration with the Functional 
Genomics Centre of the University of Verona (Prof. Massimo Delledonne), by the use of 
Illumina’s next generation sequencing HiSeq 1000 instrument, TruSeq Sample 
Preparation Kit and cBot Automated Cluster Generation System. 
Starting with 3µg of total RNA, the first step in the workflow involves purifying the poly-
A containing mRNA molecules using poly-T oligo-attached magnetic beads. Following 
purification, the mRNA is fragmented into small pieces using divalent cations under 
elevated temperature. The cleaved RNA fragments are copied into first strand cDNA 
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using reverse transcriptase and random primers. This is followed by second strand cDNA 
synthesis using DNA Polymerase I and RNase H. These cDNA fragments then go through 
an end repair process, the addition of a single ‘A’ base, and then ligation of the adapters. 
The products are then purified and enriched with PCR to create 
(Figure 6). 
Fig 6. TruSeq RNA Sample Prep Purification Workflow.
Purify and fragment mRNA
using poly-T oligo attached magnetic beads using two rounds of purification. During the 
second elution of the poly
synthesis (Figure 7A). 
Synthesize first strand cDNA
fragments primed with random hexamers into first strand cDNA using reverse 
transcriptase and random primers. The optimized random hexamer priming strategy 
provides the most even coverage
Synthesize second strand cDNA
a replacement strand to generate ds cDNA, AMPure beads are used to separate the ds 
cDNA from the second strand reaction mix(Figure 7
 28 
the final cDNA library 
 
 
. The process purifies the poly-A containing mRNA molecules 
-A RNA, the RNA is also fragmented and primed for cDNA 
. This process reverse transcribes the cleaved RNA 
 across transcripts. 
. This process removes the RNA template and synthesizes 
B). 
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Fig 7. Optimized TruSeq RNA sample preparation. Starting with total RNA, mRNA is polyA-selected and fragmented (A). It 
then undergoes first- and second-strand synthesis to produce products ready for library construction (B). 
The TruSeq DNA Sample Preparation Kits are used to prepare DNA libraries with insert 
sizes from 300-500bp for, single, paired-end, and multiplex sequencing. Library 
construction begins with either double-stranded cDNA synthesized from RNA. Blunt-end 
DNA  fragments are generated using a combination of fill-in reactions and exonuclease 
activity. 
Adenylate 3’ ends. A single ‘A’ nucleotide is added to the 3’ ends of the blunt fragments 
to prevent them from ligating to one another during the adapter ligation reaction. A 
corresponding single ‘T’ nucleotide on the 3’ end of the adapter provides a 
complementary overhang for ligating the adapter to the fragment. This strategy ensures 
a low rate of chimera (concatenated template) formation. 
Ligate adapters. This process ligates multiple indexing adapters to the ends of the ds 
cDNA, preparing them for hybridization onto a flow cell. Adapters contain unique index 
sequences that are ligated to sample fragments allowing the samples to be pooled and 
then individually identified during downstream analysis. Ligated fragments of the range 
of 75bp are isolated via gel extraction and amplified using limited cycles of PCR. 
Enrich DNA fragments. This process uses PCR to selectively enrich those DNA fragments 
that have adapter molecules on both ends and to amplify the amount of DNA in the 
library. The PCR is performed with a PCR primer cocktail that anneals to the ends of the 
adapters. The number of PCR cycles should be minimized to avoid skewing the 
representation of the library. PCR enriches for fragments that have adapters ligated on 
both ends. Fragments with only one or no adapters on their ends are by-products of 
inefficiencies in the ligation reaction. Neither species can be used to make clusters, as 
fragments without any adapters cannot hybridize to surface bound primers in the flow 
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cell, and fragments with an adapter on only one end can hybridize to surface bound 
primers but cannot form clusters. 
Validate library. Illumina recommends performing the following procedures for quality 
control analysis on sample library and quantification of the DNA library templates. 
- Quantify library. In order to achieve the highest quality of data on Illumina 
sequencing platforms, it is important to create optimum cluster densities across 
every lane of every flow cell. This requires accurate quantization of DNA library 
templates. Quantify your libraries using qPCR according to the Illumina 
Sequencing Library qPCR Quantification Guide. 
- Quality control. First, load 1 μl of the resuspended construct on an Agilent 
Technologies 2100 Bioanalyzer using a DNA specific chip such as the Agilent 
DNA-1000. Then, check the size and purity of the sample. The final product 
should be a band at approximately 100 bp (for paired-end read libraries) (Figure 
8). 
 
Fig 8.  Example of TruSeq RNA sample prep v2 library size distribution and 260bp PCR product. 
Normalize and pool libraries. Following the denaturation and amplification steps 
libraries can be pooled with up to 8 samples per lane (40 sample per flow cell) for cluster 
generation on cBot. This process describes how to prepare DNA templates that will be 
applied to cluster generation.  
Processed samples can be amplified on cBot Automated Cluster Generation System and 
used with Illumina’s next generation sequencing HiSeq 1000 instrument. 
The Illumina flow cell accommodate multiplexed pool of five samples. During the cluster 
generation process, library fragments are hybridized to oligonucleotides, that 
correspond to the sequence of the adapters ligated during the sample preparation 
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stage, on the surface of the flow cell. Single-stranded, adapter-ligated fragments are 
bound to the surface of the flow cell exposed to reagents for polymerase-base 
extension. The hybridized fragments are copied by 3’ extension and the original 
fragments are denatured leaving the immobilized copies on the flow cell surface. During 
isothermal amplification, the fragments loop over to hybridize to neighboring 
oligonucleotides to form a DNA bridge. The DNA bridge is copied and forms a double-
stranded “DNA bridge”, which is then denatured to form two ssDNA strands. Repeated 
denaturation and extension (35 times) results in localized amplification of single 
molecules in millions of unique locations across the flow cell surface. After the 
amplification process is completed, the reverse strands are removed by specific base 
cleavage, leaving the forward strands. After this process the flow cell contains 
>200,000,000 clusters with ~1,000 molecules/cluster, and is ready to be sequencing on 
the Illumina HiSeq (Figure 9). 
 
Fig 9. Cluster generation on a flowcell using the illumina cBot Cluster Generation System. Figure 8A shows hybridization of 
library fragments to the oligonucleotide on the surface of flow cell (A), the looping of a single-stranded copied fragment 
(B), subsequent amplification forming a double-stranded “DNA bridge”(C), and denaturation (D). The final illustration in 
Figure (E) shows a clonal cluster after the isothermal amplification and denaturation process has been repeated several 
times. Image from http://www.illumina.com/.  
The Illumina sequencing run generates raw data in the form of a series of images, which 
are analyzed in three different steps: image analysis, base calling, and sequence analysis. 
Illumina Sequencing Control Software (SCS) runs on the instrument, to perform real-
time image analysis and base calling. Any signal above background identifies the physical 
location of a cluster, and the fluorescent emission identifies which of the four bases was 
incorporated at that position. This image represent the data collected for the first base, 
cycles are repeated, one base at time, generating a series of images each representing a 
single base extension at a specific cluster. Base calls are derived with an algorithm that 
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identifies the emission color over time. At this time reports of useful Illumina reads 
range from 100 bases (Figure 10). 
 
Fig 10. Illumina HiSeq 1000 sequencing chemistry. Figure 10A shows the nucleotide incorporation and laser excitation 
during the first cycle for four clusters. Figure 10B illustrates the first image base calls of the clusters. Figure 410C shows 
the nucleotide incorporation and laser excitation during a second cycle. Figure 10D is the second cycle base calls of the 
clusters. Figure 10E shows the base calls of the four clusters for the first five cycles of the sequencing run. Image from 
http://www.illumina.com/. 
Because RNA-Seq reads are short, the first task is challenging. Current mapping 
strategies (Marioni JC. et al, 2008; Mortazavi A. et al, 2008; Sultan M. et al, 2008) include 
alignment procedures designed to localize reads to known exons in the genome. 
3.6 Reads alignment 
Sequence alignment is the first step in the analysis of a new RNA-Seq data. Read 
alignment was conducted uging the human genome sequence as reference.  The 
purpose of alignment is to determine the location of the reference genome sequence 
that matches with the read sequence . Once each read has been aligned downstream 
bioinformatic tools estimate the sequence of all transcripts targeted by the reads  (e.g. 
for digital gene expression). 
Alignment was conducted using the computer program Bowtie. Bowtie (Langmead B. et 
al, 2009) enables ultrafast and memory-efficient alignment of large sets of sequencing 
reads to a reference genome without relying on existing annotation. Bowtie indexes the 
reference genome using a technique borrowed from data-compression, the Burrows-
Wheeler transform (Burrows M. et al, 1994; Ferragina P. et al, 2001). 
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3.7 Transcript quantification 
After aligning reads to the reference genome the gene expression levels of each 
transcript can be estimated.  
Transcript quantification is the estimation of relative abundances at gene levels. RSEM 
(RNA-Seq by Expectation Maximization) is a software package for performing gene level 
quantification from RNA-Seq raw data (Li B. et al, 2011). The primary output of RSEM 
consists of one file for gene (or isoform)-level estimates. Abundance estimates are given 
in terms of two measures. The first is an estimate of the number of fragments that are 
derived from a given gene. The second measure of abundance is the estimated fraction 
of transcripts made up by a given gene. 
3.8 Differential Expression (DE) analysis 
Reads counts were used for statistical analysis using DESeq package of R/Bioconductor 
environment, an open source statistical package (http://www.r-project.org/), to 
determine differential expression at the gene level.  Since RNA-seq technology results in 
discrete measurement of gene expression and statistical methods developed based on 
normal distributions are not directly applicable, researchers have developed several 
methods based on discrete distributions (binomial, Poisson, and negative binomial) to 
model the gene counts directly. For the DESeq analysis, differential expression testing 
was performed using the negative binomial test on variance estimated and size factor 
normalized data (Anders S. et al, 2010). Benjamini-Hochberg correction is performed to 
filter for a set of differentially expressed genes that have a certain false discovery rate 
(FDR) due to multiple hypothesis testing. 
3.9 Gene Set Enrichment Analysis (GSEA) 
Lists of differentially expressed genes identified as significant by statistical analysis of 
gene expression data and differentially expressed of almost 2 folds in ASDs respect to 
controls have been tested for pathways analysis. 
In an attempt to uncover common fractions among the DE genes, we classified genes 
into gene ontology groups using DAVID (Dennis G. et al, 2003), bioinformatics resource, 
which is able to extract biological features/meaning associated with large gene lists. 
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Fisher’s exact test was used to calculate a p-value determining the probability that the 
biological function assigned to the analysis is explained by chance alone. GSEA, or 
pathway enrichment analysis, provides a means of integrating the results of DE genes in 
a known molecular/biological pathway. The common gene set/pathway databases 
include KEGG (Kanehisa M. et al, 2000), Biocarta and the gene ontology (GO) databases 
(Gene Ontology Consortium, 2006). 
3.10 Outlier-Gene Analysis 
Outlier-gene analysis have been performed on cases’ group (27 subjects) calculating the 
Z score for each gene by using the “scale” function in R. First was calculated the mean 
and SD for each expressed gene in cases. Then was selected a cutoff of 3.5 standard 
deviations to define whether a gene was an outlier in probands.  
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4. RESULTS 
 
This study is part of a Telethon project which has been started in 2009 and involves 
different Italian clinical and research groups; it aims to analyze gene expression 
variations in ASD subjects, characterized for CNVs potentially involved in the onset of 
autism. LCLs transcriptome of 27 ASD probands and 23 health controls have been 
analyzed through Next Generation Sequencing technology (RNA Sequencing). 
4.1 Genomic characterization 
A total of 27 ASD subjects, carrying genomic imbalances, from the whole sample have 
been selected for gene expression analysis: eight subjects were selected for the 
presence of the 22q13.3 deletion syndrome, involving the last 5 Mb, and 19 subjects for 
the presence of potentially causative CNVs. 
CNVs potentially involved in the onset of ASDs were selected for the presence of at least 
one of the following four criteria: genomic imbalances already associated with ASDs in 
literature or containing genes previously correlated to ASD; CNVs within genes involved 
in brain development, neuronal functioning, synaptic plasticity or, in general, genes 
expressed in central nervous system; regions involving unknown transcripts and gene-
desert regions; rare CNVs (frequency < 1%). 
Array-CGH analysis revealed 24 interesting copy number variants in 19 patients. In table 
1 the patients and their relative CNVs are given. 
Sample ID CHR Size (kb) Type 
867/10 chr20:14105407-14439297 333.89 del 
1380/10 chr16:81640000-81672514 32.51 del 
1414/10 chr9:1495137-1582306 87.17 del 
1449/10 chr10:34925193-34961448 36.26 del 
1494/10 chr9:7003793-8207768 1203.98 del 
1531/10 chr2:160120557-160360995 240.44 del 
1553/10 chr4:187179173-187355125 175.95 dup 
 
chr6:24390126-24491606 101.48 del 
1593/10 chr17:30711469-30787396 75.93 del 
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chr16:14876356-16199682 1323.33 dup 
1613/10 chr6:71018624-71095644 77.02 dup 
1649/10 chr5:155189273-155433297 244.02 del 
 
chr17:58403458-58441144 37.69 dup 
 
chrX:15238518-15604496 365.98 dup 
1654/10 chr8:47062622-47857974 795.35 del 
1675/10 chrX:140145377-140591773 446.4 dup 
1692/10 chr3:61640711-61686826 46.12 del 
1730/10 chr13:42312014-42721603 409.59 dup 
1733/10 chr6:45107837-45138076 30.24 del 
 
chr22:24170487-24281368 110.88 del 
1773/09 chrX:112662992-112854590 191.6 dup 
1853/09 chr2:43574302-43749060 174.76 dup 
3676 4p16.2 146 dup 
3843 20p12.1 25 dup 
Table 1. List of subjects with CNVs selected for gene expression analysis. CNV the nucleotide position in reference 
genome (GRCh37) or cytogenetic band position for each CNV, size (kb) and type (duplication, dup or a deletion, del) are 
given for each subject (sample ID).  
Five CNVs are rare variants, 6 CNVs contains gene desert region, 3 CNVs contain genes 
and/or genomic regions already associated with autism, the last 10 CNVs involve genes 
with a neuronal function. 
Thirteen CNVs are deletions with a medium size of 256.79 kb (min. 30.24 kb - max. 
1203.98 kb) whereas 11 CNVs are duplications with an average size of 306.66 kb (min. 
25 kb – max. 1323.33 kb).  
All the 50 subjects selected for gene expression analysis, listed in table 2, included 27 
patients (case group) and 23 non affected subjects (control group). These latter healthy 
siblings of probands or  other health siblings enrolled in the study and matched for sex 
and age. 
Autism patients with 22 deletion syndrome and those with autism, belonging to family 
collection, are listed in Table2 together with controls. Sex and age are also indicated. 
Sample ID Affection status Sex Age 
ME1 Autism (22q13.3 deletion syndrome) F 6 
ME2 Autism (22q13.3 deletion syndrome) F 5 
ME3 Autism (22q13.3 deletion syndrome) F 11 
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ME4 Autism (22q13.3 deletion syndrome) M 11 
ME5 Autism (22q13.3 deletion syndrome) M 21 
ME7 Autism (22q13.3 deletion syndrome) M 5 
ME8 Autism (22q13.3 deletion syndrome) F 5 
ME9 Autism (22q13.3 deletion syndrome) F 15 
867/10 Autism M 7 
1380/10 Autism F 5 
1414/10 Autism F 3 
1449/10 Autism F 9 
1494/10 Autism M 18 
1531/10 Autism M 10 
1553/10 Autism M 3 
1593/10 Autism F 6 
1613/10 Autism M 8 
1649/10 Autism F 11 
1654/10 Autism M 3 
1675/10 Autism M 4 
1692/10 Autism M 6 
1730/10 Autism M 9 
1733/10 Autism M 5 
1773/09 Autism M 9 
1853/09 Autism M 21 
3676 Autism F 7 
3843 Autism M 6 
40/11 Control M 7 
106/10 Control M 7 
130/11 Control F 5 
259/10 Control M 8 
1375/10 Control F 14 
1412/10 Control F 9 
1415/10 Control M 8 
1421/10 Control M 9 
1422/10 Control F 18 
1448/10 Control M 6 
1471/10 Control F 7 
1493/10 Control F 4 
1538/10 Control M 3 
1551/10 Control F 5 
1596/10 Control M 2 
1619/10 Control F 13 
1622/10 Control F 10 
1652/10 Control M 16 
1695/10 Control F 6 
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1736/10 Control F 12 
1762/09 Control M 13 
1774/09 Control F 7 
1857/09 Control F 22 
Table 2. Expression analysis cohort. 50 subjects with affection status, sex and age. 
The case group included 16 males and 11 females, with a mean age of 8 ± 5.06 years. 
The control group included 10 males and 13 females, with a mean age of 9 ± 4.96 years. 
4.2 LCL achievement 
LCL establishment and array CGH experiments were carried out at the same time. Thus, 
LCLs were established in our laboratory for 106 subjects, consisting of 67 ASD probands, 
and 39 healthy siblings. Starting from peripheral blood samples, leukocytes were 
separated and transformed by Epstein-Barr virus (EBV). Each LCL was maintained in 
culture for about six weeks. 
For each LCL, at least 25 millions of cells, with a mean viability of 87%, have been 
stocked in liquid nitrogen, while 100 millions cells for line (88% mean viability) were 
pelleted and resuspended in 10 ml TRIzol® for gene expression experiments. 
4.3 RNA obtainment, quantification and quality analysis  
RNA from the selected 50 LCLs has been extracted in triplicate showing a mean yield of 
75.85 µg (min 36.24 µg and max 105.72 µg) concentration of 1914 ng/µL (min 896 ng/µL 
and max 2925 ng/µL), an absorbance A260/280 ratio of 1.97 and an absorbance 
A260/230 ratio of 2.1.  
An additional DNAse digestion step was performed to ensure that the samples were not 
contaminated with genomic DNA. After DNase treatment, the average yield of RNA was 
6,45 µg (min 4.84 µg  and max 8.21 µg )174.2 ± 13 ng/µl (min 130.82 ng/µl and max 
222.02 ng/µl) and each RNA sample had an A260:A280 ratio above 1.95 and A260:A230 
ratio above 1.70 (Table3).  
RNA is a thermodynamically stable molecule, which is, however, rapidly digested in the 
presence of the nearly ubiquitous RNase enzymes. The average RIN value for the 50 
samples, after DNase treatment, is 9.9 (min 9.3 – max 10), based on a scale from 1 to 10 
 __________________________________________________________________ 
  39 
 
(Table 3). The RIN value recommended for obtaining meaningful gene expression data is 
greater than or equal to 8. As an example, the following figure shows the RNA 
Bioanalyzer trace of the 1774/09 sample (Figure 11). 
 
Fig 11. Agilent BioAnalyzer output of 1774/09 sample. The electropherogram and associated image of virtual agarose 
separation are given. In the output RIN value, RNA concentration and 28S/18S ratio are indicated. 
Sample ID Yield (µg) ng/ul 260/280 260/230 RIN 
40/11 6.64 179.36 2.01 1.93 9.7 
106/10 5.33 144 1.98 1.77 9.8 
130/11 6.72 181.75 2.01 1.87 9.6 
259/10 6.49 175.49 2.01 1.98 10 
867/10 6.54 176.83 2.00 1.85 9.9 
1375/10 6.22 168.21 2.01 1.93 10 
1380/10 6.90 186.47 1.96 1.90 9.8 
1412/10 6.24 168.65 1.98 1.77 9.9 
1414/10 6.56 177.31 1.99 1.96 10 
1415/10 6.35 171.6 2.02 1.95 10 
1421/10 6.59 178.23 2.00 1.97 9.7 
1422/10 6.56 177.27 2.00 1.87 9.4 
1448/10 6.49 175.29 1.99 1.98 9.9 
1449/10 6.36 171.78 1.99 1.90 9.4 
1471/10 5.86 158.31 1.99 2.00 9.6 
1493/10 6.90 186.46 2.00 1.95 9.9 
1494/10 6.47 174.95 2.00 1.95 10 
1531/10 6.41 173.17 2.00 1.93 9.8 
1538/10 4.84 130.82 1.99 1.86 9.8 
1551/10 6.45 174.36 1.99 1.99 10 
1553/10 6.47 174.96 1.97 1.89 9.3 
1593/10 6.91 186.89 1.96 1.92 9.6 
1596/10 6.29 169.92 1.98 1.87 9.8 
1613/10 6.56 177.18 2.00 2.00 10 
1619/10 6.30 170.19 1.96 1.82 10 
1622/10 6.50 175.56 2.00 1.96 10 
1649/10 5.89 159.3 1.99 1.76 9.8 
1652/10 6.60 178.46 1.99 1.94 9.5 
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1654/10 6.35 171.51 1.94 1.95 9.3 
1675/10 6.79 183.4 2.01 2.01 10 
1692/10 7.14 192.93 1.99 1.99 9.9 
1695/10 6.24 168.75 1.97 1.85 9.4 
1730/10 7.16 193.55 2.00 1.94 9.7 
1733/10 8.21 222.02 2.01 2.04 9.9 
1736/10 6.50 175.81 1.96 1.95 9.3 
1762/09 6.53 176.61 1.99 1.99 10 
1773/09 6.29 169.89 2.00 1.88 9.7 
1774/09 6.48 175.18 2.01 1.98 10 
1853/09 6.46 174.67 1.96 1.88 9.8 
1857/09 6.76 182.58 2.00 1.89 10 
ME1 5.79 156.44 1.99 1.80 9.7 
ME2 6.33 171.14 1.98 1.94 9.9 
ME3 6.65 179.77 2.00 1.70 9.8 
ME4 5.72 154.55 1.99 1.67 10 
ME5 6.57 177.5 1.99 1.89 10 
ME7 5.98 161.5 2.01 1.84 10 
ME8 6.22 168.11 2.01 1.93 9.8 
ME9 6.22 168.2 2.02 1.94 9.5 
3676 6.85 185.26 2.00 1.86 10 
3843 6.58 177.92 1.97 1.95 9.6 
Table 3. RNA quantity and quality after DNase treatment for each sample. Total amount of RNA (µg), RNA concentration 
(ng/µl), 260/280 and 260/230 ratio and RIN value are given.  
4.4 RNA Sequencing 
We sequenced 50 RNA specimens, obtaining an average of 20 million reads per sample, 
with a range from 10.2 million to 57.4 million reads. 22000, out of 37500 genes present 
in human db, resulted to be expressed in at least one sample (by at least one read). The 
top 10 most expressed genes are EEF1A1, ACTB, GAPDH, ACRG1, EEF2, RPL3, CD74, 
TMSB4X, ENO1 and RPLP0 (table 4), accounting for the 7.11% of the total reads per 
samples. The most expressed gene is EEF1A1, eukaryotic translation elongation factor 1 
alpha 1, which is covered on average by 41000 reads for each sample. 
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Gene ID baseMean foldChange log2FoldChange pval gene symbol 
ENSG00000156508 410944.42 1.00 0.01 0.93 EEF1A1 
ENSG00000075624 186797.85 1.06 0.08 0.21 ACTB 
ENSG00000111640 170848.71 1.06 0.08 0.37 GAPDH 
ENSG00000184009 110510.42 0.99 -0.02 0.86 ACTG1 
ENSG00000167658 98452.05 0.98 -0.03 0.81 EEF2 
ENSG00000100316 91541.19 1.02 0.03 0.69 RPL3 
ENSG00000019582 91303.86 1.02 0.02 0.54 CD74 
ENSG00000205542 91254.01 1.06 0.08 0.23 TMSB4X 
ENSG00000074800 88252.13 1.01 0.02 0.82 ENO1 
ENSG00000089157 82516.02 1.01 0.02 0.74 RPLP0 
Table 4. List of the most expressed genes in LCLs. Ensemble gene name, base mean reads, fold change (number 
describing how much a expression changes in cases respect controls), log2fold change, p-value and gene symbol are 
given. Gene description is given in Appendix 1. 
4.5 Differentially expressed genes (DEG) and gene set enrichment analysis (GSEA) 
Analysis of differential expression genes has been performed with the case-control 
design including 27 ASD and 23 control samples. 
This analysis identified 295 differentially expressed genes (DEG) with a statistically 
significant nominal p-value (p< 0.05). The top 10 most differentially expressed genes 
between cases and controls are RP11-632C17_A.1, ZNRD1, SFRP1, RNF183, TRIM26, 
HLA-DRA, VPS37B, FTL, TRIM27 and PPP1R18 (Table 5). However, after correction of 
multiple tests no gene was significantly DE.  
Gene ID baseMean foldChange log2FoldChange pval gene symbol 
ENSG00000230202 205.97 172.44 7.43 3.24E-05 RP11-632C17__A.1 
ENSG00000224859 20.21 0.01 -6.75 0.0004 ZNRD1 
ENSG00000104332 61.02 0.08 -3.72 0.0005 SFRP1 
ENSG00000165188 31.91 0.24 -2.08 0.0017 RNF183 
ENSG00000230230 122.09 0.10 -3.26 0.0033 TRIM26 
ENSG00000206308 10936.83 1.76 0.82 0.0034 HLA-DRA 
ENSG00000139722 655.03 1.41 0.50 0.0037 VPS37B 
ENSG00000087086 29840.91 1.19 0.25 0.0046 FTL 
ENSG00000237071 100.69 0.12 -3.11 0.0047 TRIM27 
ENSG00000231247 186.46 0.07 -3.87 0.0049 PPP1R18 
Table 5. The top ten differentially expressed genes between cases and controls. Gene description is given in Appendix 1. 
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The 266 genes, which are differentially expressed of almost 2 folds in cases respect to 
controls, have been selected for
recognized by the tool for the following analysis. KEGG 
demonstrated that 10 different pathways are over represented
enriched pathways is reported in Figure 12.
Term 
hsa05320:Autoimmune thyroid disease
hsa05310:Asthma
hsa04612:Antigen processing and presentation
hsa05330:Allograft rejection
hsa05322:Systemic lupus erythematosus
hsa05332:Graft-versus-
hsa04940:Type I diabetes mellitus
hsa04672:Intestinal immune network for IgA production
hsa05416:Viral myocarditis
hsa04514:Cell adhesion molecules (CAMs)
Table 6. DAVID annotation chart of DEG, showing t
listed according to their enrichment p
gene list (%) and padj (adjusted p-value) are shown
Fig 12. Antigen processing and presentation pathway. M
red star. (Source: BIOCARTA databases).
Six genes are shared in the four most significant enriched
belong to HLA gene region
differentially expressed in DEG analysis and
possible to attribute a haplotype to 
 42 
 DAVID pathway analysis. 138 out of 266
functional classification of genes 
 (Table 6
 
Count % pvalue 
 7 5.07 1.38E-06 
 6 4.35 1.61E-06 
 8 5.80 1.66E-06 
 6 4.35 4.94E-06 
 8 5.80 5.47E-06 
host disease 6 4.35 7.42E-06 
 6 4.35 1.08E-05 
 6 4.35 2.33E-05 
 6 4.35 1.42E-04 
 7 5.07 3.28E-04 
he enriched functional annotation pathways associated to gene list, 
-value. Number of genes (count) involved in given term, percentage respect to input 
. 
ajor histocompatibility complex, class II, genes are indicated by a 
 
 pathways and all of them 
 (chromosome 6p21.3). Thus, focus on all HLA genes resulted 
 through the Ensembl gene name
seven out of 10 HLA genes (Table 7). 
 
 genes are 
). One of the 
padj 
8.15E-05 
9.52E-05 
9.78E-05 
2.91E-04 
3.22E-04 
4.38E-04 
6.37E-04 
0.0013748 
0.0083314 
0.0191427 
 
 it was 
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Gene ID foldChange pval Gene symbol Haplotype 
ENSG00000241106 0.55 0.036 HLA-DOB 6p21.3 
ENSG00000232062 28.78 0.042 HLA-DQA1 Ssto 
ENSG00000206301 0.3 0.013 HLA-DQA2 Mcf 
ENSG00000237541 0.08 0.041 HLA-DQA2 6p21.3 
ENSG00000231286 1.95 0.017 HLA-DQB1 Mcf 
ENSG00000232351 1.74 0.037 HLA-DQB1-AS1 Mcf 
ENSG00000206308 1.76 0.003 HLA-DRA mcf/ssto 
ENSG00000228080 3.03 0.029 HLA-DRB1 ssto 
ENSG00000227669 1.7 0.044 HLA-H dbb 
ENSG00000206341 1.4 0.047 HLA-H 6p21.3 
 Table 7. List of HLA-DEG. Haplotype name or map position are given. Gene description is given in Appendix 1. 
4.6 DEG analysis and GSEA on 22q13.3qter 
A differential expression analysis was performed on a subgroup of patients 
characterized for the deletions at the chromosome 22q13.3qter. Eight ASDs cases (3 
males and 5 females; mean age 10 ± 5.97) and eight controls (2 males and 6 females; 
mean age 10 ± 5.96).  
The top 10 most differentially expressed genes between cases and controls were 
FRMD4B, BRD2, PNRC2, HMGA2, RP11-290F5.2, HLA-DMA, HIST1H1C, RP11-366L20.2, 
SHROOM3 and ZBED4 (Table 8). In this analysis three genes resulted differentially 
expressed in ASDs respect to controls with a significant p-adjusted value (p-adj < 0.05). 
gene ID baseMean foldChange log2FoldChange pval padj gene symbol 
ENSG00000114541 120.59 0.17 -2.52 4.22E-08 0.001 FRMD4B 
ENSG00000234704 792.65 23.75 4.57 1.08E-07 0.002 BRD2 
ENSG00000189266 1607.62 0.31 -1.68 7.97E-07 0.009 PNRC2 
ENSG00000149948 57.81 0.05 -4.45 1.39E-05 0.113 HMGA2 
ENSG00000180712 515.47 0.4 -1.31 2.99E-05 0.194 
RP11-
290F5.2 
ENSG00000241394 405.66 0.02 -5.72 3.70E-05 0.2 HLA-DMA 
ENSG00000187837 843.54 2.27 1.18 4.83E-05 0.224 HIST1H1C 
ENSG00000197301 7.82 0.08 -3.59 6.71E-05 0.272 
RP11-
366L20.2 
ENSG00000138771 165.7 0.2 -2.32 0.0001 0.364 SHROOM3 
ENSG00000100426 928.64 0.5 -1.01 0.0003 1 ZBED4 
Table 8. The most DEG in 22q13.3qter analysis. Ensemble gene name, fold change value, log2 Fold Change, p-value, p-
value adjusted and gene name. Gene description is given in Appendix 1. 
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Four hundred and forty eight genes with a significant nominal p-value and differentially 
expressed of almost 2 times in ASDs respect to controls were submitted to DAVID 
functional annotation chart. The tool recognized 341 genes. Results of the pathway 
enrichment analysis are listed in table 9. Analysis a total of 10 pathways were identified 
using KEGG database. 
Term Count % PValue padj 
hsa04612:Antigen processing and presentation 9 2.65 2.95E-04 0.036 
hsa05322:Systemic lupus erythematosus 9 2.65 9.74E-04 0.115 
hsa04940:Type I diabetes mellitus 6 1.77 0.0016 0.186 
hsa04360:Axon guidance 9 2.65 0.0052 0.478 
hsa05330:Allograft rejection 5 1.47 0.0063 0.546 
hsa05332:Graft-versus-host disease 5 1.47 0.0084 0.651 
hsa05416:Viral myocarditis 6 1.77 0.0157 0.862 
hsa04672:Intestinal immune network for IgA production 5 1.47 0.0184 0.902 
hsa05320:Autoimmune thyroid disease 5 1.47 0.0211 0.93 
hsa04514:Cell adhesion molecules (CAMs) 7 2.06 0.0565 0.999 
Table 9. DAVID annotation chart of DEG analysis on 8 ASD subjects with 22qter deletion and 8 controls. 
4.7 Outlier genes 
The term “outlier genes” is used to reflect that the dysregulated gene is contained 
within a structural variation and shows significant alteration in gene expression. The 
identification of outlier genes has been performed in all the 27 ASD cases. We have 
identified 68 dysregulated genes in 17 ASD subjects (Table 10). 
ID sample gene ID CHR POS gene symbol 
867/10 ENSG00000114473 3 197615946 IQCG 
867/10 ENSG00000112511 6 33378176 PHF1 
867/10 ENSG00000204531 6 31130253 POU5F1 
867/10 ENSG00000211934 14 106452671 IGHV1-2 
1414/10 ENSG00000081985 1 67773047 IL12RB2 
1414/10 ENSG00000118689 6 108977549 FOXO3 
1414/10 ENSG00000179165 6 36358778 PXT1 
1414/10 ENSG00000167123 9 131174030 CERCAM 
1414/10 ENSG00000171840 12 673462 NINJ2 
1414/10 ENSG00000088387 13 99445741 DOCK9 
1414/10 ENSG00000088387 13 99445741 DOCK9 
1414/10 ENSG00000170468 14 73957644 AC005280.1 
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1414/10 ENSG00000101335 20 35169887 MYL9 
1449/10 ENSG00000214776 12 9620148 RP11-726G1.1 
1494/10 ENSG00000129474 14 23447821 JUB 
1494/10 ENSG00000205609 16 28390900 EIF3CL 
1531/10 ENSG00000162738 1 160389283 VANGL2 
1531/10 ENSG00000038427 5 82849181 VCAN 
1531/10 ENSG00000106268 7 2281857 NUDT1 
1531/10 ENSG00000171914 15 62682725 TLN2 
1553/10 ENSG00000196284 6 44777054 SUPT3H 
1553/10 ENSG00000182534 17 74680745 MXRA7 
1593/10 ENSG00000157873 1 2487078 TNFRSF14 
1593/10 ENSG00000145495 5 10353815 MARCH6 
1593/10 ENSG00000107372 9 74966341 ZFAND5 
1593/10 ENSG00000230224 10 102008028 PHBP9 
1593/10 ENSG00000187066 11 64852451 AP003068.6 
1593/10 ENSG00000227825 12 98847613 SLC9A7P1 
1593/10 ENSG00000119688 14 74766602 ABCD4 
1593/10 ENSG00000166783 16 15729851 KIAA0430 
1593/10 ENSG00000250251 16 15219099 PKD1P6 
1593/10 ENSG00000179889 16 15068599 PDXDC1 
1593/10 ENSG00000182149 16 71958311 IST1 
1593/10 ENSG00000255185 16 70096958 RP11-106J23.2 
1593/10 ENSG00000237296 16 22448329 RP11-368J21.1 
1593/10 ENSG00000247061 17 2574352 AC005696.2 
1593/10 ENSG00000171791 18 60790579 BCL2 
1593/10 ENSG00000101346 20 30804468 POFUT1 
1593/10 ENSG00000197976 X 1710518 AKAP17A 
1613/10 ENSG00000131016 6 151561134 AKAP12 
1654/10 ENSG00000185090 1 38259474 MANEAL 
1654/10 ENSG00000186603 1 45792545 HPDL 
1654/10 ENSG00000137198 6 16290176 GMPR 
1654/10 ENSG00000104267 8 86376243 CA2 
1654/10 ENSG00000127564 16 3018103 PKMYT1 
1654/10 ENSG00000174292 17 7284365 TNK1 
1654/10 ENSG00000005206 19 2328629 AC004410.1 
1654/10 ENSG00000188130 22 50683879 MAPK12 
1675/10 ENSG00000198794 15 75287939 SCAMP5 
1692/10 ENSG00000197262 17 34639793 CCL4L2 
1730/10 ENSG00000185668 1 38509523 POU3F1 
1730/10 ENSG00000116741 1 192778273 RGS2 
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1730/10 ENSG00000082781 3 124567206 ITGB5 
1730/10 ENSG00000137731 11 117672445 FXYD2 
1730/10 ENSG00000182253 15 99645286 SYNM 
1730/10 ENSG00000100979 20 44527399 PLTP 
1733/10 ENSG00000117115 1 17393256 PADI2 
1733/10 ENSG00000236756 10 75006946 C10orf103 
1733/10 ENSG00000211895 14 106173457 IGHA1 
1733/10 ENSG00000188636 22 44888452 LDOC1L 
1733/10 ENSG00000130822 X 152952080 PNCK 
1773/09 ENSG00000182095 7 5346421 TNRC18 
1773/09 ENSG00000156299 21 32638612 TIAM1 
1853/09 ENSG00000015568 2 110550335 RGPD5 
1853/09 ENSG00000134762 18 28570052 DSC3 
3676 ENSG00000204469 6 31588450 PRRC2A 
3676 ENSG00000234745 6 31321649 HLA-B 
3843 ENSG00000147394 X 152082986 ZNF185 
 Table 10. List of the 68 dysregulated genes. For each sample, the Ensembl gene name, the position on chromosome and 
gene symbol are indicated. Gene description is given in Appendix 1. 
Among them, the three outlier genes KIAA0430 (chromosome 16: 15,688,243-
15,737,023), PDXDC1 (chromosome 16:14,876,356-16,199,683) and PKD1P6 
(chromosome 16: 15,219,099-15,248,421) are located in a region that was found 
duplicated in one autistic subject (1593/10) and reported as an ASD potentially involved 
CNV on chromosome 16 (already found in ASDs) (Table 9). The position of the 
duplication is chr16:14876356-16199682 and has a size of 1323.326 KB. 
ENGname CHR POS gene name ID sample CNV 
ENSG00000166783 16 15688243-15737023 KIAA0430 1593/10 chr16:14876356-16199682 
ENSG00000179889 16 15068833-15131552 PDXDC1 1593/10 chr16:14876356-16199682 
ENSG00000250251 16 15219099-15248421 PKD1P6 1593/10 chr16:14876356-16199682 
Table 9. The three outlier genes located within a duplicated CNV. The Ensembl gene name, the chromosome, the 
nucleotide position, the gene symbol, Id sample and the position of the CNV. 
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5. DISCUSSION 
 
In this study, 19 ASD individuals, carrying genomic imbalances, potentially involved in 
the disease, 8 individuals with 22qter deletion syndrome and 23 controls, have been 
analyzed for whole gene expression profile by next generation sequencing (RNA-Seq), to 
identify altered pathway between cases and controls and better understand the 
pathological role of the CNVs in ASDs. Expression experiments were carried out using 
mRNA extracted from LCLs. 
5.1 Technical controls 
From the methodological point of view, both quality and quantity of RNA were found to 
be optimal. The mean RIN value observed in the 50 samples is 9.9, which is much higher 
compared to the threshold of 8, usually considered as standard quality cut-off for RNA-
Seq analyses. These data confirmed that starting materials were good enough for 
subsequent experiments. Although it is well recognized that biases and sequence errors 
can be introduced during RNA fragmentation and cDNA synthesis (Kassahn KS. et al, 
2011), technical quality controls associated with library generation and deep sequencing 
were exceeded. 
5.2 Copy Number Variants 
The discovery of rare and recurrent CNVs as important pathogenic mutations in ASDs 
was a watershed in ASD genetics. Recurrent CNVs such as those at 16p11.2, 22q11.2, 
1q21.1, 7q11.23 and 15q11-q13 show statistically significant association with the 
disease (Sebat J . et al, 2007; Marshall CR. et al, 2008; Ramalingam A. et al, 2011). Our 
incomplete understanding of structural polymorphism, such as CNVs, and the 
appreciation that ASDs show a high degree of clinical variance and incomplete 
penetrance is blurring clear-cut genotype-phenotype correlations. The advent of 
commercially available microarrays has facilitated the implementation of molecular 
karyotyping in laboratories. The resolution offered by these arrays allows the detection 
of larger aberrations with high confidence, but at the same time leads to the detection 
of a high number of smaller CNVs for which causality often remains to be elucidated.  
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Since each of the genomic variants were private (observed sporadically and not common 
to two or more subjects) in our study, it was not possible to state a correlation between 
CNV and disease status. Lack of recurrence may in fact reflect an underlying reality that 
autistic behavior can result from many different genomic defects. However, 3  of the 
observed CNV (located in 20p12.1, 4p16.2 and 16p13.11 regions) were already 
associated with ASD in other studies (Sebat J . et al, 2007; Marshall CR. et al, 2008; 
Ramalingam A. et al, 2011) 
5.3 Differentially expressed genes (DEG) and gene set enrichment analysis (GSEA) 
DEG and GSEA were performed on the whole cohort (27 cases and 23 controls). Gene 
expression information was integrated within our study to check whether a specific 
biological pathway is associated with the disorder. The aim is to attempt to identify 
those pathways  that are statistically over-represented or under-represented in DEG list.  
Even if 295 genes were DE, no significant adjusted p-value was observed after correction 
for multiple test. Some explanations of this result can be attributed to the fact that 
there is no real difference between cases and controls or the method of correction used 
was too severe or that the study is underpowered to find significant differences in the 
two groups. Thus, we submitted to GSEA a set of 266 DEG that showed a FC of 2 and a p-
value < 0.05. This analysis identified a total of 10 enriched pathways (Table 4), that are 
predominately related to autoimmune disease and antigen processing and presentation 
pathways.  
It is no surprise to see immune gene associations in ASDs, as numerous researchers have 
reported immune abnormalities in autism for over 20 years. It has become increasingly 
clear that inflammatory processes are related with autism and recent genetic research 
has also associated numerous immune function genes with autism (Gregg JP. et al, 2008; 
Enstrom AM. et al, 2009; Morgan JT. et al, 2010; Voineagu I. et al, 2011). 
Moreover, Sweeten and colleagues (2003a) observed that monocyte counts were 
increased in autistic children suggesting that the immune system was over activated in 
ASDs. Two studies found that the prevalence of autoimmune disorders in the families 
with autistic children was higher than in control subjects (Comi AM. et al, 1999; Sweeten 
TL. et al, 2003b). 
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Interestingly, a metanalysis study found that SNPs of human leukocyte antigen (HLA) 
region were associated with schizophrenia (Stefansson H. et al, 2009). Current research 
is increasingly demonstrating a role for HLA proteins in neural cell interactions, synaptic 
function, cerebral hemispheric specialization, central nervous system (CNS) 
development (Xiao BG. et al, 1998; Huh GS. et al, 2000; Boulanger LM. et al, 2004; 
Cullheim S. et al, 2007; Ohtsuka M. et al, 2008) and even neurological disorders (Bailey 
SL. et al, 2006). 
It has been reported that autism subjects often show associations with HLA 
genes/haplotypes, suggesting an underlying dysregulation of the immune system 
mediated by HLA genes (Torres AR. et al, 2002; Chien YL. et al, 2012; Mostafa GA. et al, 
2013). 
The HLA region on chromosome 6p21 (about 4x10
6
 bp) is of major interest in basic 
research as well as medicine as genes/proteins in this region are involved in many 
biological processes such as histocompatibility, inflammation, ligands for immune cell 
receptors, and the complement cascade. The HLA region has 20 typical HLA genes and 
112 nontypical HLA genes that are inherited together as frozen blocks of DNA called 
ancestral or extended haplotypes.  
We focus on 7 HLA genes and 1 HLA pseudogene that resulted differentially expressed 
(DE) (Table 5), confirming the implication of HLA loci in our ASD dataset. Interestingly, 
we found that MHC class I (i.e. HLA-H pseudogene) and MHC class II (i.e. HLA-DOB, HLA-
DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB1-AS1, HLA-DRA and HLA-DRB1) genes are 
differentially expressed in cases respect to controls. Moreover, since complete DNA 
sequences have been published for 8 of the most common haplotypes in the European 
population (Horton R. et al, 2008), it was possible to attribute reference haplotypes for 
some of aforementioned HLA genes. For example, the highest expression of HLA-SSTO 
haplotype in cases compared to controls (FC: 28.78; p-value: 0.042) suggests that it is 
the most frequent haplotype in our samples. 
HLA-DM and –DQ, class II proteins have structures like classical antigen-binding HLA 
proteins and work in the cytoplasm of antigen presenting cells. It is now known that 
DQ2 is a poor substrate for DM and it has been proposed that antigen presentation in 
the thymus and periphery can be affected by impaired DQ-DM interactions so as to 
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promote autoimmune disease (Hou T. et al, 2011). The altered expression of HLA-DQ in 
our ASD subjects is a proof in support of this theory. In ASDs the over-expression of HLA-
DQA1 and HLA-DQB1 and HLA-DQB1-AS could be a compensative response to the 
under-expression of HLA-DQA2 aiming to form the heterodimer . 
5.4 DEG and GSEA on 22q13.3qter 
Classification of autistic patients on the basis of genotypic and phenotypic information is 
one effective way to identify more homogeneous subgroups and hasten the 
identification of genes underlying autism (Folstein SE. et al, 2001; Belmonte MK et al, 
2004; Veenstra-Vanderweele J. et al, 2004; Muhle R. et al, 2004). So we made a 
differential expression analysis on the subgroup of the 8 ASD patients with the deletion 
22q13.3qter, against 8 sex and age matched controls. 
Affected individuals with 22q13.3 deletions were enrolled because SHANK3 gene, a 
strong candidate gene for the neurobehavioral symptoms, is located in that deleted 
region. SHANK3 gene has became the best candidate gene for the neurological deficits 
(developmental delay and absent speech) in the last years (Bonaglia MC. et al, 2001). 
In our dataset SHANK3 gene results under-expressed with a FC of 0.8, a p-value of 0.74 
and a baseMean of 5.83 reads. Probably, we were not able to detect any significant 
difference due to the fact that the gene is less expressed in LCLs than in brain and 
because lymphoblastoid cell lines are not neuronal cells and some of our findings might 
not reflect the pathophysiology in ASD brains. 
However, we also explore the functional impact or 22q13.3 deletion. Previously, it was 
unclear which genes are  dysregulated nearby the 22qter region or whether there is a 
common expression signature shared by 22q13.3 cases. We found that 6 genes, BRD1 
(p-value 0.002), PIM3 (p-value 0.032), TRABD (p-value 0.016), SBF1 (p-value 0.007), 
ZBED4 (p-value 0.0003) and CHKB (p-value 0.024), surrounding SHANK3 gene region in 
the nearest 500 kb, are all under-expressed with a significant p-value. Our analysis, then, 
shows a positive correlation between expression level  and deletion. 
The most differentially expressed genes are: FRMD4B (FERM domain containing 4B), 
BRD2 (bromodomain containing 2) and PNRC2 (proline-rich nuclear receptor coactivator 
2). FRMD4B and PNRC2 genes are located respectively to 3p14.1 and 1p36.11 loci. BRD2 
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gene encodes a transcriptional regulator that belongs to the BET (bromodomains and 
extra terminal domain) family of proteins. This protein associates with transcription 
complexes and with acetylated chromatin during mitosis and has been implicated in 
juvenile myoclonic epilepsy. Notably, BRD2 gene maps to the major histocompatability 
complex (MHC) class II region on chromosome 6p21.3, the same region identified in the 
DE study of the whole sample. However, sequence comparison suggests that the protein 
is not involved in the immune response. 
GSEA demonstrates that there is specific enrichment of autoimmune disorders pathway 
(systemic lupus erythematosus, type I diabetes mellitus) in probands, supporting the 
hypothesis that ASDs are associated with immune genes.  
Moreover, this analysis highlights the axon guidance pathway. Axon guidance (also 
called axon pathfinding) is a subfield of neural development concerning the process by 
which neurons send out axons to reach the correct targets. Axons often follow very 
precise paths in the nervous system. Genetics and biochemistry have identified a large 
set of molecules that affect axon guidance. How all of these pieces fit together is less 
understood. 
Previous studies found decreased expression of axon-guidance proteins in the brains of 
subjects with autism, and suggest that dysfunctional axon-guidance protein expression 
may play an important role in the pathophysiology of autism (Suda S. et al, 2011). Our 
differential expression analysis revealed that significant difference concerning neuronal 
growth is detectable in LCLs. 
5.5 Outlier genes 
We next asked whether CNVs could cause transcriptional changes and, conversely, 
whether dysregulated  genes can aid in characterizing structural chromosomal variation. 
To assess which dysregulated genes could be associated to higher risk of disease, we 
investigated expression variance in each of the ASD probands (27 cases) and we looked 
for genes (outliers) with an expression deviation of at least 3.5 SD. To explore the 
functional impact of CNVs in ASDs at a genome-wide scale, our query searched for  the 
overlap between location of structural-variation data and transcriptional data as well. 
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We found 68 outlier genes in 17 of the 27 ASD subjects. In particular, we observed an 
hyper-expressed region corresponding to a CNV presenting a duplication. In fact, three 
outlier genes (KIAA0430, PDXDC1 and PKD1P6), belonging to a unique subject (1593/10), 
cluster within a potentially involved CNV of several KB on chromosome 16, already 
found associated in autism (Ramalingam A. et al, 2011).  
PKD1P6 (polycystic kidney disease 1 - autosomal dominant - pseudogene 6) is a known 
pseudogene, that has 6 alternative processed transcripts that don’t contain an open 
reading frame (ORF) and cannot be translated. KIAA0430 (limkain-b1) encodes a 
putative peroxisomal protein that appears to be an essential regulator of oogenesis 
required for female meiotic progression. It acts by down-regulating RNA transcripts, 
either at transcriptional of post-transcriptional level. In humans, it may be 
autoantigenic. PDXDC1 encodes a pyridoxal-dependent decarboxylase domain 
containing 1. Even if RNA-Seq expression data from Illumina’s Human BodyMap 2.0 
project detected expression of these three genes in brain tissue 
(http://www.ensembl.info/blog/2011/05/24/human-bodymap-2-0-data-from-illumina/), 
the three genes we found within the duplication are no obvious candidates for autism. 
The 16p13.11 aberration is located in areas with high locus control regions (LCR) 
content. There are several paralogous repeats at the proximal and distal breakpoint (She 
X. et al, 2004). The repeats are in direct orientation and non allelic homologous 
recombination (NAHR) between these LCRs seems to be a likely explanation for the 
recurrence of this rearrangement (Finelli P. et al, 2004; Ullmann R. et al, 2007; Ballif BC. 
et al, 2007). Evidence for the involvement of genes on 16p13 has also come from linkage 
and association studies that have identified autism susceptibly loci in this region (Lamb 
JA. et al, 2005; Philippe A. et al, 1999; Weiss LA. et al, 2008). Ulmann et al (2007) 
proposed two genes (NDE1; nudE nuclear distribution E homolog 1 and NTAN1; N-
terminal asparagine amidase) plausibly involved in autism. We recognize the stringency 
of the analysis is very high. Lowering the strength could was possible to find some 
relevant candidates located in the region. 
In this analysis, the most of outlier genes do not locate within CNVs. We focus, in fact, 
only on the CNVs potentially causative of ASDs. Further analysis will be performed using 
the whole CNVs dataset obtained from array-CGH. 
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5.5 Conclusions 
Results highlight different immunological (autoimmune diseases, antigen processing and 
presentation) and cell adhesion molecular pathways associated to ASDs. GSEA 
conducted on 22qter subjects suggest an involvement of axon guidance pathway, which 
contributes to the assembly and function of neural circuitry, confirming that LCLs exhibit 
genetic biomarkers relevant to autism.  
We performed DNA-mRNA correlations based on genomic and gene expression data. 
We use the outlier gene approach to identify candidate ASD regions. The 16p13.1 
duplication contains three expressed genes, all of which are over-expressed in ASD LCLs. 
The outlier study demonstrates the utility of gene-expression analysis in evaluating the 
functional consequences of rare functional structural variations in a human 
neuropsychiatric disease (ASDs). Further analysis will be also extended on the entire 
CNVs dataset, aiming to identify correlation between gene expression and structural 
variations. Moreover, analysis designed specifically to examine associations between 
cases and controls, as well as their family members, will be performed to study the 
segregation of the genetic factors. 
The strength of this study is that transcriptome analysis was performed on a large 
number of samples using a high-throughput sequencing technology (RNA-Seq). The use 
of RNA-Seq offers several key advantages: RNA-Seq is not limited to detect known 
transcripts and can reveal the precise location of transcription boundaries (i.e. spicing 
junctions), at a single-base resolution. In addition, RNA-Seq can also reveal sequence 
variations (for example SNPs and indel) in the transcribed regions, gene alleles, 
differently spliced transcripts, non-coding RNAs and gene fusions. All these features will 
be used to perform association studies. 
This research helps understanding the genetic bases for ASD pathophysiology and 
unravelling potential new pathways involved in ASDs. Together with studies addressing 
epigenetic modifications and comprehensive analysis of environmental risk factors, 
these pieces of information can be better  integrated to improve our understanding of 
the molecular basis of ASDs, and foster the development of early preventive and 
corrective strategies. 
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7. APPENDIX 
 
Appendix 1 
Official gene symbol Description 
ABCD4 ATP-binding cassette, sub-family D (ALD), member 4 
AC004410.1 signal peptide peptidase like 2B  
AC005280.1 pseudogene 
AC005696.2 N/A 
ACTB actin, beta 
ACTG1 actin, gamma 1 
AKAP12 A kinase (PRKA) anchor protein 12 
AKAP17A A kinase (PRKA) anchor protein 17A  
AP003068.6 Putative protein coding 
BCL2 B-cell CLL/lymphoma 2 
BRD1 bromodomain containing 1  
BRD2 bromodomain containing 2 
C10orf103 chromosome 10 open reading frame 103 
CA2 carbonic anhydrase II 
CCL4L2 chemokine (C-C motif) ligand 4-like 1; chemokine (C-C motif) ligand 4-like 2 
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain 
CERCAM cerebral endothelial cell adhesion molecule 
CHKB choline kinase beta  
DOCK9 dedicator of cytokinesis 9 
DSC3 desmocollin 3 
EEF1A1 
eukaryotic translation elongation factor 1 alpha-like 7; eukaryotic translation 
elongation factor 1 alpha-like 3; eukaryotic translation elongation factor 1 
alpha 1 
EEF2 eukaryotic translation elongation factor 2 
EIF3CL eukaryotic translation initiation factor 3, subunit C-like 
ENO1 enolase 1, (alpha) 
FOXO3 forkhead box O3; forkhead box O3B pseudogene 
FRMD4B FERM domain containing 4B 
FTL similar to ferritin, light polypeptide; ferritin, light polypeptide 
FXYD2 FXYD domain containing ion transport regulator 2 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GMPR guanosine monophosphate reductase 
HIST1H1C histone cluster 1, H1c 
HLA-B major histocompatibility complex, class I, C; major histocompatibility complex, 
class I, B 
HLA-DMA major histocompatibility complex, class II, DM alpha 
HLA-DOB major histocompatibility complex, class II, DO beta 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 
HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1; similar to major histocompatibility complex, class II, DQ beta 1 
HLA-DQB1-AS1 HLA-DQB1 antisense RNA 1  
HLA-DRA major histocompatibility complex, class II, DR alpha 
HLA-DRB1 major histocompatibility complex, class II, DR beta 4; major histocompatibility 
complex, class II, DR beta 1 
HLA-H major histocompatibility complex, class I, H (pseudogene) 
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HMGA2 high mobility group AT-hook 2 
HPDL 4-hydroxyphenylpyruvate dioxygenase-like 
IGHA1 immunoglobulin heavy constant alpha 1 
IGHV1-2 immunoglobulin heavy variable 1-2 
IL12RB2 interleukin 12 receptor, beta 2 
IQCG IQ motif containing G 
ITGB5 integrin, beta 5 
JUB jub, ajuba homolog (Xenopus laevis) 
KIAA0430 KIAA0430 
LDOC1L leucine zipper, down-regulated in cancer 1-like 
MANEAL mannosidase, endo-alpha-like 
MAPK12 mitogen-activated protein kinase 12 
MARCH6 membrane-associated ring finger (C3HC4) 6 
MXRA7 matrix-remodelling associated 7 
MYL9 myosin, light chain 9, regulatory 
NINJ2 ninjurin 2 
NUDT1 nudix (nucleoside diphosphate linked moiety X)-type motif 1 
PADI2 peptidyl arginine deiminase, type II 
PDXDC1 pyridoxal-dependent decarboxylase domain containing 1 
PHBP9 prohibitin pseudogene 9  
PHF1 PHD finger protein 1 
PIM3 pim-3 oncogene  
PKD1P6 polycystic kidney disease 1 (autosomal dominant) pseudogene 6 
PKMYT1 protein kinase, membrane associated tyrosine/threonine 1 
PLTP phospholipid transfer protein 
PNCK pregnancy up-regulated non-ubiquitously expressed CaM kinase 
PNRC2 proline-rich nuclear receptor coactivator 2; similar to hCG1728885 
POFUT1 protein O-fucosyltransferase 1 
POU3F1 POU class 3 homeobox 1 
POU5F1 POU class 5 homeobox 1 
PPP1R18 protein phosphatase 1, regulatory subunit 18  
PRRC2A proline-rich coiled-coil 2A  
PXT1 peroxisomal, testis specific 1 
RGPD5 RANBP2-like and GRIP domain containing 5 
RGS2 regulator of G-protein signaling 2, 24kDa 
RNF183 ring finger protein 183 
RP11-106J23.2 Known processed transcript 
RP11-290F5.2 Putative processed transcript 
RP11-366L20.2 N/A 
RP11-368J21.1 nuclear pore complex interacting protein pseudogene (LOC613037), non-
coding RNA 
RP11-632C17__A.1 pseudogene 
RP11-726G1.1 pseudogene 
RPL3 ribosomal protein L3; similar to 60S ribosomal protein L3 (L4) 
RPLP0 
ribosomal protein, large, P0 pseudogene 2; ribosomal protein, large, P0 
pseudogene 3; ribosomal protein, large, P0 pseudogene 6; ribosomal protein, 
large, P0 
SBF1 SET binding factor 1  
SCAMP5 secretory carrier membrane protein 5 
SFRP1 secreted frizzled-related protein 1 
SHANK3 SH3 and multiple ankyrin repeat domains 3  
SHROOM3 shroom family member 3 
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SLC9A7P1 solute carrier family 9, subfamily A (NHE7, cation proton antiporter 7), member 7 pseudogene 1  
SUPT3H suppressor of Ty 3 homolog (S. cerevisiae) 
SYNM synemin, intermediate filament protein 
TIAM1 T-cell lymphoma invasion and metastasis 1 
TLN2 talin 2 
TMSB4X thymosin-like 2 (pseudogene); thymosin-like 1 (pseudogene); thymosin beta 4, X-linked 
TNFRSF14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry 
mediator) 
TNK1 tyrosine kinase, non-receptor, 1 
TNRC18 trinucleotide repeat containing 18 
TRABD TraB domain containing  
TRIM26 tripartite motif-containing 26 
TRIM27 tripartite motif-containing 27 
VANGL2 vang-like 2 (van gogh, Drosophila) 
VCAN versican 
VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) 
ZBED4 zinc finger, BED-type containing 4 
ZFAND5 similar to zinc finger, AN1-type domain 5; zinc finger, AN1-type domain 5 
ZNF185 zinc finger protein 185 (LIM domain) 
ZNRD1 zinc ribbon domain containing 1 
 
Table 10. List of genes mentioned in this study. Official gene symbol and description are shown. 
